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SUMMARY 
Malassezia spp. are commensals of the canine skin flora. Opportunistic skin infections involving 
overgrowth of Malassezia are often found in intertriginous areas or associated with one or several 
underlying medical conditions affecting the host defence of the skin barrier. Symptoms include 
pruritus, erythema, alopecia, lichenification, hyperpigmentation, scaling and moist skin surface with a 
greasy, malodorous exudate. A diagnosis of Malassezia dermatitis is indicated when skin with 
cutaneous lesions and Malassezia overgrowth responds to antifungal therapy.  
Treatments available with the indication of Malassezia overgrowth include both systemic treatment 
with azole derivatives or allylamine and a wide variety of agents for topical treatment. Available 
topical treatment options include azole derivatives and antimicrobial agents, many of which lack 
sufficient evidence base. Therefore, the need for randomized, controlled trials evaluating topical 
antimicrobial agents available and marketed for Malassezia overgrowth is urgent.  
The purpose of this study was to evaluate the efficacy of a new topical product, Crystavet® (1% 
hydrogen peroxide, Bioglan, Malmö, Sweden), for the treatment of Malassezia overgrowth in a 
prospective, open, randomized, controlled study design using a split-body protocol. In total, 22 
anatomically distinct skin areas from ten dogs were included. The efficacy of Crystavet was compared 
to a reference product of 4% chlorhexidine and evaluated based primarily on the reduction of 
Malassezia yeast obtained by cytology. Secondly, the efficacy was evaluated by quantitative culture of 
Malassezia spp., clinical skin lesion score and degree of pruritus pre and post treatment.   
Treatment with both Crystavet and the reference product reduced Malassezia population sizes and 
clinical parameters significantly, without any difference in efficacy noted between the products. No 
adverse reactions were recorded and owners rated the treatment as easy to perform. These results 
suggest that topical treatment with Crystavet (1% hydrogen peroxide) is effective and safe for the 
treatment of localized Malassezia overgrowth in dogs. The results also suggest that the antifungal 
efficacy of 1% hydrogen peroxide is similar to that of 4% chlorhexidine for Malassezia species. 
Further studies including a larger sample size are needed to confirm these results.  
  
SAMMANFATTNING 
Malassezia spp., även kallad jästsvamp, är en del av hundens normala mikroflora. Opportunistiska 
hudinfektioner med jästsvampsöverväxt uppstår ofta i intertriginösa områden eller sekundärt till 
medicinska tillstånd som påverkar hudens barriär och försvarsmekanism. Kliniska tecken som uppstår 
är klåda, erytem, alopeci, lichenifikation, hyperpigmentering, mjäll samt en fuktig hudyta med 
illaluktande sekret. Diagnosen jästsvampsdermatit är verifierad när en inflammerad och skadad hudyta 
med jästsvampsöverväxt läker av efter svampdödande behandling.  
Både systemiska och topikala behandlingsalternativ finns att tillgå för behandling av 
jästsvampsöverväxt. För systemisk behandling används azolderivat eller allylamin medan topikala 
alternativ innefattar både azolderivat samt en mängd antimikrobiella substanser. För flertalet av dessa 
saknas tillräcklig evidens. Det finns därför ett stort behov av randomiserade, kontrollerade studier som 
utvärderar effekten av topikala behandlingsalternativ för jästsvampsöverväxt.  
Syftet med den här studien var att utvärdera effektiviteten av en 1% väteperoxid baserad produkt, 
Crystavet® (Bioglan, Malmö, Sweden), vid behandling av jästsvampsöverväxt hos hund i en 
prospektiv, öppen, randomiserad, kontrollerad studie. Ett split-body protokoll användes och Crystavets 
effektivitet jämfördes med en 4% klorhexidinprodukt som referens. Totalt inkluderades 22 anatomiskt 
skilda hudområden från tio hundar. Behandlingens effektivitet utvärderades i förstahand baserat på 
minskning av antalet jästsvampar påvisade via cytologi. I andra hand utvärderades behandlingens 
effekt genom kvantitativ odling av jästsvamp, kliniska lesionscore och grad av klåda innan och efter 
behandling.   
Behandling med både Crystavet och referensprodukt resulterade i en signifikant minskning av 
jästsvampar och kliniska mätvärden, behandlingarna skiljde sig inte signifikant åt i sin effektivitet. 
Inga biverkningar rapporterades och djurägarna ansåg att behandlingen var enkel att utföra. Resultat 
från den här studien indikerar att topikal behandling med Crystavet (1% väteperoxid) är effektivt och 
säkert att använda vid behandling av lokaliserad jästsvampsöverväxt hos hund. Resultaten tyder även 
på att den jästsvampsdödande effekten av 1% väteperoxid är jämförbar med den hos 4% klorhexidin 
för jästsvampar av genuset Malassezia. Vidare studier med en större studiepopulation krävs för att 
bekräfta dessa resultat.  
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INTRODUCTION 
Malassezia is the scientific name of one genus of microorganism known as yeast. Malassezia spp. are 
recognized as commensals of the canine skin flora but are also known to cause opportunistic skin and 
ear infections (Cafarchia et al., 2005; Machado et al., 2011; Nardoni et al., 2004; Nuttall, 2012; Prado 
et al., 2008).  
Treatments available for the indication of Malassezia dermatitis include both systemic with azole 
derivatives and a wide variety of antimicrobial topical treatments. Out of the several available 
alternatives for topical treatment only a few have been reported effective in treating Malassezia 
dermatitis as reviewed by Mueller et al (2012) as well as Negre et al (2009).  
The purpose of this study was to evaluate the efficacy of a new topical product, Crystavet® (1% 
hydrogen peroxide, Bioglan, Malmö, Sweden), for the treatment of Malassezia overgrowth in canines.  
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LITERATURE REVIEW  
Malassezia species 
Malassezia species are eukaryotic, unicellular organisms of the Fungi kingdom, also known as yeasts, 
which reproduce by budding (Miller et al., 2013a; Nuttall, 2012). The genus of Malassezia has been 
revised several times and new species are continuously discovered. Currently 14 species are accepted 
which have been isolated from both healthy and diseased skin of mammals (Gaitanis et al., 2012). The 
genus is divided into one lipophilic, non-lipid dependent species, M. pachydermatis, and 13 lipid 
dependent species. Although, recently published data of whole genome sequencing suggests lipid-
dependence of all Malassezia spp.(Gaitanis et al., 2012; Wu et al., 2015)   
Malassezia species in canines 
Malassezia is part of the normal micro flora of skin in healthy dogs and several other mammals 
(Kennis et al., 1996; Miller et al., 2013a; Nuttall, 2012). Based on their study of early colonization of 
commensal Malassezia in healthy puppies, Wagner and Schadler (2000) concluded that colonisation 
occurs soon after birth, since they isolated Malassezia from puppies as young as 3 days old.  
Out of the 14 known species, Malassezia pachydermatis is especially prevalent in canine isolates from 
both healthy and dermatologically diseased dogs (Cafarchia et al., 2005; Machado et al., 2011; 
Nardoni et al., 2004; Nuttall, 2012). Some of the lipid-dependent Malassezia spp. have also been 
isolated from both skin of dogs with cutaneous lesions and from healthy dogs. These include: M. 
furfur and M. sympodialis (Cafarchia et al., 2011; Machado et al., 2011; Nardoni et al., 2004; Raabe et 
al., 1998) as well as M. globosa, M. restricta, M. sloofiae, M. nana and M. obtusa (Khosravi et al., 
2016). Within each species of the Malassezia genus there are different genotypes that may cohabitate 
or infect the same animal or anatomical site (Cafarchia et al., 2011, 2008; Castellá et al., 2005; Puig et 
al., 2016). 
In healthy dogs of various breeds, the Malassezia population size varies widely in different anatomical 
areas within and between individuals, but will in most areas be < 10 yeasts/1.25 cm2 (Bond et al., 
1995c; Cafarchia et al., 2005; Kennis et al., 1996, 1996; Nardoni et al., 2007). However, Bond and 
Lloyd (1997, 1998) found that population sizes of M. pachydermatis was significantly higher in 
healthy Basset hounds compared to other dogs of various breeds. 
Many anatomical areas, such as periorbital, perianal, inguinal, the dorsal neck and the conjunctival 
sacs, have been found to be populated with Malassezia spp./M. pachydermatis in healthy dogs. The 
most frequent areas of isolation in healthy dogs varies between studies but includes the perioral, 
interdigital and perianal skin and the external ear canal (Bond et al., 1995c; Bond and Anthony, 1995; 
Cafarchia et al., 2005; Kennis et al., 1996; Prado et al., 2008, 2004).  
Age does not seem to influence the frequency of isolation in canines (Mauldin et al., 1997; Miller et 
al., 2013a; Plant et al., 1992) although Nardoni et al (2004) did isolate Malassezia spp. more 
frequently in dogs aged 1-5 years compared to dogs of other ages. In another study by Machado et al 
(2011), age-related differences found in Malassezia spp. isolation were by the authors themselves 
believed to be due to a, false positive, statistical error.  
Malassezia associated dermatitis in canines 
Malassezia dermatitis is an inflammation of the skin associated with Malassezia yeast overgrowth 
(Miller et al., 2013a). The first report of Malassezia as a cause of canine dermatitis was published in 
1970s by Dufait (1975) and almost twenty years later Plant et al (1992, pp. 881–882) suggested that 
“the prevalence of cutaneous Malassezia infection in dogs may not be rare, as previously reported.” 
This is further supported by several more recent studies were the frequency of isolation and population 
size of  Malassezia yeast in dogs with cutaneous lesions is reported to be significantly higher 
compared to healthy dogs (Cafarchia et al., 2005; Machado et al., 2011; Nardoni et al., 2004; Prado et 
al., 2008). For example Machado et al (2011) isolated Malassezia spp. in culture from 52.9% of the 
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dogs with cutaneous lesions compared to 15.6%of the healthy dogs. In the same study a linear trend 
was found between increasing lesional scores and Malassezia population counts obtained by fungal 
culture. Several studies have also shown that treatment targeted on eliminating Malassezia yeasts in 
dogs with Malassezia overgrowth and concurrent dermatitis results in a decrease of cutaneous lesions 
(Bensignor, 2008; Bond et al., 1995b; Maynard et al., 2011; Pinchbeck et al., 2002).  
Clinical lesions and signs  
Canine Malassezia dermatitis presents as a pruritic skin disease with one or several of the following 
manifestations: erythema, alopecia, lichenification, hyperpigmentation, scaling and moist skin surface 
with a greasy, malodorous exudate. Chronic cases often present with more pronounced alopecia, 
lichenification and hyperpigmentation. The manifestations are either generalized or localized (Bond et 
al., 1995b; Cafarchia et al., 2005; Mason and Evans, 1991; Mobley and Meyer, 1994; Nuttall, 2012). 
Intertriginous areas such as skin folds and interdigital skin as well as areas perioral, ventral abdomen, 
inguinal, the ventral neck, axillae and the medial aspects of the extremities, are often affected (Bond et 
al., 1995b; Cafarchia et al., 2005; Mason and Evans, 1991; Mauldin et al., 1997; Mobley and Meyer, 
1994). 
Malassezia spp. can also cause inflammation of the external ear canal, which can be concurrent with 
Malassezia dermatitis, but is defined as an ear inflammation (otitis externa) and not as dermatitis 
(Bond et al., 1995b; Miller et al., 2013b). The findings of Prado et al (2004) also suggest that 
Malassezia spp. could be involved  in the pathogenesis of corneal ulcers, or at least be an aggravating 
factor.  
Pathogenicity and risk factors 
For Malassezia to become pathogenic, overpower of the host defence (physical, chemical and 
immunological defences) is necessary, which is achieved by changes in both the host and the yeast 
organism (Nuttall, 2012). For Malassezia pachydermatis this includes virulence factors such as the 
ability to produce enzymes like lipase, phosphatase, protease and urease. These enzymes may alter the 
local pH and break down dermal components, causing activation of inflammatory mediators (Coutinho 
and Paula, 2000; Lautert et al., 2011; Mathieson et al., 1998; Nuttall, 2012). Phospholipase activity 
seems to play an particularly important role as a virulence factor (Cafarchia et al., 2008; Machado et 
al., 2010).  
Mason and Evans (1991) stated two categories of host related factors that contributes to allowing 
commensals to become pathogenic: the first being changes in microclimate of the skin that benefits 
proliferation of the organisms and the second being failure of the host´s immune defence to respond to 
and control the overgrowth. An example of a factor that can change the microclimate is occlusion, 
something that occurs in intertriginous areas such as skin folds or interdigital skin areas. Occlusion 
leads to increased humidity and accumulation of debris, desquamated epidermal cells, sweat and 
sebum on the skin, which induces dermal inflammation single-handedly and creates a 
microenvironment favourable for yeast organisms (Bond et al., 2004). The Malassezia overgrowth 
further drives the inflammation and both clinical and histopathological lesions increase in severity. 
Bond et al (2004) also showed that a larger Malassezia population size can by itself lead to dermal 
inflammation. In contrast Bensignor et al (2002) found large population sizes on healthy, non lesional, 
pinnae of Basset Hounds.  Supporting the findings of Bond et al (2004), regarding the fact that large 
Malassezia populations and an occluded, moist skin climate can cause disease, are the findings of 
Uchida et al (1992). Uchida et al (1992) induced otitis externa following a single application of a M 
pachydermatis suspension into the external ear canal of dogs. Noteworthy is that in the study by Bond 
et al (2004) in which Malassezia dermatitis was induced, the majority of the dogs recovered 
spontaneously after ceasing to apply the Malassezia solution and occluding the skin surface. This 
illustrates the importance of host defence in the pathogenesis of Malassezia dermatitis, as some of the 
dogs were not able to clear the infection when the underlying trigger of disease was no longer present 
(Bond et al., 2004).  
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Factors that also affect both microclimate of the skin and the host’s capability of defence are 
underlying medical conditions leading to dermatoses that precedes the Malassezia dermatitis, only to 
mention a few: ectoparasitosis, cutaneous adverse food reactions, endocrinopathies and seborrhoeic 
dermatitis/keratinization defects (Bond and Lloyd, 1997, 1998; Mauldin et al., 1997; Nuttall, 2012; 
Plant et al., 1992). Another frequently reported association is that between atopic dermatitis and 
Malassezia dermatitis (Bond et al., 1996, 1994; Mauldin et al., 1997; Nardoni et al., 2004). The 
association is complex, since the highest population sizes of Malassezia yeasts are sometimes, but not 
always, found on lesional skin (Bond et al., 1994; Nardoni et al., 2007) and even normal population 
sizes of Malassezia might cause inflammation in dogs with atopic dermatitis if an underlying 
hypersensitivity for Malassezia yeasts is present (Nuttall and Halliwell, 2001). In fact, independent of 
Malassezia counts, atopic dogs show higher levels of Malassezia-specific IgG and IgE antibodies 
compered to non-atopic dogs. In non-atopic dogs these levels remain low also during concurrent 
Malassezia dermatitis (Nuttall and Halliwell, 2001).  
Since Malassezia is a commensal, there is no transmission of disease in the true sense of the word. 
There is, however, some evidence that leads to speculations that scratching and licking in dogs with 
Malassezia dermatitis could spread Malassezia organisms to other areas of the body (Cafarchia et al., 
2005). One example is in the situation when dogs have perioral lesions and larger populations of 
Malassezia yeasts on interdigital skin, which might reflect consequences of scratching and licking 
(Cafarchia et al., 2005).  
Several breeds have been reported to be at an increased risk for Malassezia dermatitis. These are: 
Basset hounds, American and English Cocker Spaniels, West Highland Terriers, English Setters, Shih 
Tzus and Dachshund (Bond et al., 1996; Mauldin et al., 1997; Plant et al., 1992). Tendencies of 
increased risk have also been reported for Boxers, Springer Spaniels and German Shepherds (Bond et 
al., 1996; Plant et al., 1992). Miller et al (2013a) also report Toy and Miniature Poodles, Cavalier King 
Charles Spaniel, Australian and Silky Terriers as breeds at an increased risk.  
No significant difference could be proven between males and females in several studies (Machado et 
al., 2011; Nardoni et al., 2004; Plant et al., 1992). In contrast, Mauldin et al (1997) have reported an 
increased risk for Malassezia dermatitis in spayed females and castrated males. 
Diagnostic testing in Malassezia dermatitis 
When presented with a clinical case with symptoms of Malassezia dermatitis, it is especially important 
to remember that there are several differential diagnoses associated with Malassezia dermatitis and 
that more than one might be relevant in one patient (Miller et al., 2013a). For detection of Malassezia 
overgrowth there are several available techniques; cytology, culture or histopathology/skin biopsies 
(Miller et al., 2013a; Nuttall, 2012). Although detection of Malassezia is important for the diagnosis, it 
has been suggested that a diagnosis should only be considered confirmed when a dog with increased 
Malassezia populations on skin with cutaneous lesions, responds to treatment with antifungal therapy 
(Bond and Lloyd, 1997; Nuttall, 2012).  
Cytology 
On microscopic examination the Malassezia yeast, with its diameter of 3-5µm and typical “peanut” or 
“Russian doll” shape, is detectable on dry lens (x400) but preferably oil immersion lens (x1000) 
should be used (Hensel et al., 2015; Nuttall, 2012). The colour will vary from light to dark blue and 
some Malassezia yeasts will not stain, but are still detectable by their visible cell wall.  
Sampling for microscopic examination of the skin surface can be done by superficial scraping, the 
rubbing of a cotton swab, direct impression of a microscopic glass slide onto the skin surface or by the 
adhesive tape strip technique, in which a clear acetate adhesive tape is pressed on the skin surface, 
then stained and placed adhesive down on glass slide (Bond et al., 1995a, 1994; Cafarchia et al., 2005; 
Machado et al., 2011; Plant et al., 1992; White et al., 1998). None of these techniques are regarded as 
gold standard (Miller et al., 2013a). When comparing the techniques of direct impression, swabbing 
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and superficial skin scrapings in healthy dogs Kennis et al (1996) found no significant difference in 
their ability to recover yeast organisms. In contrast, White et al (1998) found that superficial scraping 
yielded higher quantities of yeasts compared to cotton swabs. 
No exact number of Malassezia organism have been established as a criteria to diagnose Malassezia 
dermatitis and therefore different cut off values are used in different studies with varying study 
protocols (Bond et al., 1996, 1994; Bond and Lloyd, 1997; Cafarchia et al., 2005; Nuttall, 2012; 
Nuttall and Halliwell, 2001; Plant et al., 1992). In the study by Cafarchia et al (2005) a sterile NaCl 
moistened cotton swab was used to sample the skin surface and then rolled onto glass slides for 
microscopic evaluation. A skin sample was considered positive for Malassezia overgrowth if it had >5 
yeasts in five random fields at 40X magnification. Bond et al (1996, 1994) suggested that populations 
should be considered elevated when > 10 Malassezia yeasts are detected in 15 random fields at 
X100/oil immersion lens after sampling with tape strip technique.   
The sensitivity and specificity for cytology when considering fungal culture as a gold standard for 
detection of Malassezia spp in dogs was studied by Machado et al (2011). The specificity was found to 
be good, 100% in dogs with no cutaneous lesions and 92.7% in dogs with cutaneous lesions; while the 
sensitivity was much lower, 25% and 53.2% respectively. Similar results have been obtained by 
Cafarchia et al (2005) as well as Prado et al (2008). Especially in healthy dogs sensitivity is reported 
to be low for several cytological sampling techniques (Bensignor et al., 2002; Kennis et al., 1996)  
According to Mason and Evans (1991) cytology is the most useful diagnostic technique for the 
everyday clinician since it easily available.  
Culture 
For culture of all Malassezia species a lipid supplemented media is essential, for example modified 
Dixons’ medium, Ushijima's medium A and Leeming's media (Bond and Lloyd, 1996; Miller et al., 
2013a). For isolation of Malassezia pachydermatis exclusively, Sabouraud’s medium is used (Bond et 
al., 1995a; Bond and Lloyd, 1996; Gordon, 1979; Miller et al., 2013a). Malassezia pachydermatis 
colony appearance is reported most distinct on modified Dixons medium compared to several other 
medias, where they form buff-coloured dome shaped colonies of 1-3 mm in diameter (Bond and 
Lloyd, 1996; Nuttall, 2012). To detect and quantify Malassezia in culture an incubation time of three 
up to ten days and a temperature of 28-37°C should be used (Bond et al., 1996, 1995a, 1995c, 1994; 
Bond and Lloyd, 1996; Cafarchia et al., 2011, 2005; Kennis et al., 1996; Machado et al., 2011; 
Nardoni et al., 2007, 2004; White et al., 1998). Noteworthy is that population sizes of Malassezia 
pachydermatis do not vary significantly between an incubation time of three and seven days at 32°C 
but will be significantly lower on day three compared to day seven if cultivated at 26°C (Bond and 
Lloyd, 1996). 
An aerobic atmosphere is sufficient and most commonly used (Bond et al., 1996, 1995a, 1995c, 1994, 
Cafarchia et al., 2011, 2005; Kennis et al., 1996; Machado et al., 2011; Nardoni et al., 2007, 2004; 
White et al., 1998) but carbon dioxide enriched (5-10%) air might be used and is proven to give an 
increased frequency of isolation and population size of Malassezia pachydermatis on Sabouraud’s 
medium, but not on modified Dixons medium (Bond and Lloyd, 1996; Pinchbeck et al., 2002). 
Fungal culture is used for both detection of Malassezia organisms and estimating their population 
sizes by quantitative or semi-quantitative methods. No exact number have been established for the 
diagnosis of Malassezia dermatitis although it has been proposed that populations higher than 70 
colony forming units (CFU) when sampling a ≤25 cm2 skin area with a cotton swab could be 
indicative of Malassezia overgrowth (Cafarchia et al., 2005). This suggestion was based on the mean 
of 70 CFU obtained from the healthy dogs negative on cytology but positive on culture in the study.  
Sampling techniques include sampling by direct impression of culture medium onto the skin with, for 
example, contact plates of various sizes; or by using a variety of tools such as an adhesive tape strip, a 
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sterile carpet or cotton swab for rubbing the skin, or by a detergent scrub technique (Bensignor et al., 
2002; Bond et al., 1995a, 1995c; Bond and Lloyd, 1997; Cafarchia et al., 2011, 2011, 2005; Kennis et 
al., 1996; White et al., 1998). For mucosal sites or sampling of the external ear canal cotton swabs are 
used. Few comparative studies of the techniques have been done, although one published study by 
Bond et al (1995c) found no significant difference between results obtained using contact plates and  
the detergent scrub technique in healthy dogs. A correlation between the contact plates and the 
detergent scrub technique was reported in samples from dogs with dermatitis and otitis by Bond et al 
(1995a) but populations sizes tended to be about 100 times greater when using the detergent scrub 
technique. In addition, Bond et al (1994) found fungal culture with contact plates in healthy dogs to be 
lacking in sensitivity compared to cytology as gold standard.  
Correlation of population size based on cytology and fungal culture 
Reports of correlations for population sizes between cytology and fungal culture are diverse and 
inconclusive. Correlations for calculation of population size between cytology using a tape strip 
technique and culture using contact plates was reported significant by Nuttall and Halliwell (2001) for 
dogs with both elevated/high and normal/low populations sizes. Using similar sampling techniques 
Bond et al (1995a, 1994) came to the opposite conclusion when sampling healthy dogs as well as dogs 
with dermatitis or otitis. No correlation between cytology and culture results were found in the study 
by Machado et al  (2011) although high populations on cytology correlated with a positive fungal 
culture. A weak correlation between cytology and culture was reported in healthy canines by 
Bensignor et al (2002), although ultimate population sizes obtained by cytology was reported to be 
>100 times higher than counts obtained by culture. In contrast Kennis et al (1996) found the 
population sizes obtained by culture to be significantly higher compared to cytology when sampling 
healthy dogs. 
Species differentiation 
Culture can be used for species differentiation between lipid dependent species and Malassezia 
pachydermatis due to the non-lipid dependent property of M.  pachydermatis. For this purpose M. 
pachydermatis is cultured on Sabouraud’s medium which is lipid deficient (Bond et al., 1996; Bond 
and Lloyd, 1996; Gordon, 1979; Nuttall, 2012). Further species identification cannot be done by 
culture alone and might include evaluating morphology, immunological properties and molecular 
biology or use of methods like polymerase chain reaction (PCR), rRNA sequencing analysis or Matrix 
Assisted Laser Desorption Ionization Time of Flight mass spectrometry (MALDI-TOF MS) (Gaitanis 
et al., 2012; Kolecka et al., 2014). Kolecka et al (2014) reported MALDI-TOF MS to correctly 
identify clinical isolates of Malassezia yeast by 100% on genus level and that 99.2-100% of the 
isolates were identified by species.  
Histopathology 
From samples taken for skin biopsies, Malassezia yeasts can be detected on histopathology mainly in 
surface and infundibular keratin and sometimes in hair follicles (Mauldin et al., 1997; Miller et al., 
2013a). Surface yeasts are not necessarily indicative of Malassezia dermatitis as it may occur on 
histopathology for other canine dermatological diagnoses as well, but when detected in hair follicles it 
should be considered pathognomonic for Malassezia dermatitis (Miller et al., 2013a; Scott, 1992). 
Although Malassezia yeasts are readily detectable on cytology prior to skin biopsies, they are not 
always detectable on histopathology (Mauldin et al., 1997; Mobley and Meyer, 1994). In the study by 
Mauldin et al (1997) Malassezia organisms were detectable in 73.3% of the histological preparations 
whereas Mason and Evans  (1991) reported detectable yeast in 100% of their samples from biopsies.  
Malassezia dermatitis is consistent with a histopathological reaction pattern of epidermal reactions and 
lymphocytic superficial perivascular to interstitial dermatitis (Mauldin et al., 1997). This reaction 
pattern is based on findings of parakeratotic hyperkeratosis, lymphocytic exocytosis, diffuse 
intercellular oedema and irregular epidermal hyperplasia. Other findings might be acanthosis, 
orthokeratotic hyperkeratosis, focal parakeratosis and neutrophil infiltration into epidermis and under 
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stratum corneum (Mason and Evans, 1991; Mobley and Meyer, 1994). When yeasts are detectable, a 
higher number of yeasts correlates with a more severe and pronounced parakeratosis (Mauldin et al., 
1997). The superficial dermis, is according to findings of Mason and Evans (1991), characterized with 
mild to moderate oedema and a mixed pattern of inflammatory cells including neutrophils, 
lymphocytes, plasma cells, mast cells and occasionally eosinophils. 
After challenging the skin of healthy dogs with M. pachydermatis solutions for 7 days, 
histopathological findings were similar to those of natural occurring cases of Malassezia dermatitis but 
changes were milder in degree of severity (Bond et al., 2004). 
Treatments of Malassezia dermatitis 
A wide variety of agents for both systemic and topical use have been proposed and evaluated for the 
treatment of Malassezia dermatitis (Miller et al., 2013a).  
Treatment of choice might include either or both systemic and topical treatments and should depend 
on distribution pattern, degree of severity, owner’s resources, possible adverse effects and legislation 
in the present country (Nuttall, 2012). If any underlying diseases or symptoms (e.g. dryness of skin) 
are related to the Malassezia dermatitis, they also need to be addressed with appropriate measures. 
As an example, early case series reported by Mason and Evans (1991) included the use of systemic 
ketoconazole at a dosage of 10 mg/kg twice daily for one month, combined with one or more of the 
following topical treatments: selenium sulphide shampoo twice weekly for one month, miconazole 
cream twice daily for 2 weeks, or focal treatment daily with povidone-iodone. The protocols were 
curative for all the patients (Mason and Evans, 1991).  
Systemic therapy 
Therapies available and evaluated in vivo for the treatment of Malassezia dermatitis includes azole 
derivatives (ketoconazole, itraconazole, fluconazole) and the allylamine terbinafine (Bensignor et al., 
2002; Kumar et al., 2002; Rosales et al., 2005; Sickafoose et al., 2010). Both azole derivatives and 
allylamine inhibit synthesis of ergosterol, an essential component of cell membrane in Malassezia 
yeasts, ultimately resulting in the death of the yeast cell (Miller et al., 2013a). 
There are several in vitro studies reporting a high antifungal activity against Malassezia 
pachydermatis for itraconazole, ketoconazole and terbinafine (Álvarez-Pérez et al., 2016; Cafarchia et 
al., 2012; Carrillo-Muñoz et al., 2013; Gupta et al., 2000; Yurayart et al., 2013). In contrast, the in 
vitro susceptibility of Malassezia pachydermatis to fluconazole has been reported to be much lower 
compared to other azole derivatives (Álvarez-Pérez et al., 2016; Brito et al., 2009; Cafarchia et al., 
2012; Carrillo-Muñoz et al., 2013). There is some contradictory reports regarding these in vitro 
susceptibilities, Lyskova et al (2007) reported a high antifungal activity for fluconazole and Cafarchia 
et al (2012) found the antifungal activity for terbinafine to be low.  
However, an in vitro isolate from a clinical case of canine seborrhoeic dermatitis was reported 
resistant to ketoconazole and itraconazole (Nijima et al., 2011) and Cafarchia et al (2012) found 
several strains of Malassezia pachydermatis to be cross-resistant to numerous azole compounds from 
dogs with and without skin lesions. As an example, one strain found was resistant to fluconazole, 
ketoconazole, itraconazole, voriconazole and posaconazole (Cafarchia et al., 2012). 
Fluconazole 
In a double blinded non inferiority trial by Sickafoose et al (2010) the efficacy of fluconazole was 
compared to that of ketoconazole. Twenty-five dogs were divided into two groups, either receiving 
fluconazole 5-10mg/kg q24h or ketoconazole 5-10mg/kg q24h during a period of three weeks. In 
addition, all dogs received cephalexin 22-30 mg/kg q12h since pyoderma was also an inclusion criteria 
of the study. Statistically significant reduction of cytological yeast count, clinical signs and pruritus 
was achieved by both treatments, without any statistical difference between the treatments. The 
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majority of the dogs in the study by Sickafoose et al (2010) obtained clinical resolution but a small 
majority required further treatment.  
Adverse side effects reported by Sickafoose (2010) for fluconazole include vomiting, soft stool and 
diarrhoea. These findings are also reported in the textbooks by Koch et al (2012) and Miller et al 
(2013a) with the addition of hepatotoxicity as a possible side effect. 
Itraconazole  
In a randomized controlled trial by Pinchbeck et al (2002) with 20 dogs divided into two groups, two 
dose regimes of itraconazole were compared. These were a pulse administration of itraconazole 
5mg/kg q24h for two days per week and itraconazole 5mg/kg q24h continuously. The treatment period 
for both regimes was three weeks. A significant decrease of yeast organisms as well as clinical 
severity and pruritus was reported for both regimes without any significant difference in efficacy 
between the two regimes (Pinchbeck et al., 2002). The efficacy of a pulse administration regime of 
itraconazole as described by Pinchbeck et al (2002) was also reported efficient by Bensignor (2008) 
who compared it to the efficacy of ketoconazole 10mg/kg q24h for a treatment period of three weeks. 
Both treatment regimens resulted in a reduction of Malassezia yeast population, clinical lesions and 
pruritus and no statistical significant difference in efficacy could be reported between the regimes 
(Bensignor, 2008).  
Kumar et al (2002) also reported that the use of itraconazole, 5mg/kg q24h, in combination with 
selenium sulphide shampoo twice weekly, was efficient and led to clinical resolution in 35-40 days. 
Another study by Sai Prasanna et al (2006) with the same dose regime, reported a shorter treatment 
period, the resolution of the infection was then also confirmed by cytological examination.  
No adverse side effects were reported for itraconazole in these study populations (Bensignor, 2008; 
Pinchbeck et al., 2002), although side effects reported elsewhere are hepatotoxicity, gastrointestinal 
toxicity and cutaneous vasculitis (Grooters and Taboada, 2003; Koch et al., 2012; Miller et al., 2013a). 
In addition Koch et al (2012) report anorexia as a common side effect and ulcerative dermatitis as an 
uncommon side effect.  
Ketoconazole 
The efficacy of ketoconazole in reducing yeast count, clinical lesions and pruritus have been reported 
by Bensignor (2008) in a randomized, blinded controlled study, in which ketoconazole was 
administered at 10mg/kg q24h for three weeks. Similar results were reported in the study by 
Sickafoose et al (2010) were dogs with Malassezia dermatitis and concurrent pyoderma  were treated 
with ketoconazole 5-10mg/kg q24h and cephalexin 22-30 mg/kg q12h daily for three weeks. 
Rosales et al (2005) studied the efficacy of ketoconazole as a therapy for Malassezia infection 
concurrent with pyoderma. The study was randomized, single blinded and included 20 dogs divided 
into three groups. All groups received cephalexin 22-30 mg/kg q12h, one group only received 
cephalexin and was used as a control group. The other two groups received either terbinafine at 30 
mg/kg q24h or ketoconazole 5-10 mg/kg q12h. Reduction of yeast, clinical lesions and pruritus was 
noted for all groups but only reduction of yeast was found statistically significant for ketoconazole and 
reduction of clinical lesions was only significant for the group treated exclusively with cephalexin 
(Rosales et al., 2005). In the study by Rosales et al (2005) only two of the dogs treated with 
ketoconazole resolved completely both on cytology and clinically.  
Sai Prasanna et al (2006) reported ketoconazole to be efficient at 5mg/kg once daily when combined 
with topical treatment using ketoconazole 2% shampoo twice weekly and ketoconazole cream 2% 
applied twice daily. The treatment period ranged from 15-25 days and results were evaluated by 
clinical observations and cytology.  
Rosales et al (2005) did not observe any adverse side effects in dogs receiving ketoconazole, 5-10 
mg/kg twice daily during 3 weeks, in their study. However, several studies have reported of adverse 
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side effects for the systemic treatment with ketoconazole, which include: vomiting, 
anorexia/inappetence, exhaustion and soft stool/diarrhoea (Bensignor, 2008; Mason and Evans, 1991; 
Sickafoose et al., 2010). Furthermore, ketoconazole is reported to be hepatotoxic and teratogenic, as 
well as to cause fever, thrombocytopenia,  non-regenerative anemia, pruritus and alopecia (Koch et al., 
2012; Miller et al., 2013a). Listed possible side effects for ketoconazole tablets approved for dogs in 
Sweden include apathy, ataxia, tremor, hepatotoxicity, vomiting, anorexia and diarrhoea 
(Läkemedelsindustriföreningen, 2014). In addition, ketoconazole is reported to have antiandrogenic 
and antiglucocorticoid effects (Läkemedelsindustriföreningen, 2014; Miller et al., 2013a).  
Terbinafine  
In a randomized, single blinded study by Berger et al (2012) two dose regimes of terbinafine were 
compared. Terbinafine at a dosage of 30mg/kg was either administered q24h or as a pulse 
administration q24h for two consecutive days per week. The treatment periods lasted three weeks. 
Clinical lesions, mean Malassezia population and pruritus was statistically significantly reduced for 
both treatment regimens with a significantly larger reduction of pruritus achieved by the pulse 
administration of terbinafine (Berger et al., 2012). Noteworthy is that in the study by Berger et al 
(2012) 17 of the 20 dogs treated with terbinafine required further treatment after the end of the trial.  
The in vivo efficacy of terbinafine was compared to that of ketoconazole by Rosales et al (2005) and 
found to be as efficient in reducing Malassezia populations and more efficient in reducing pruritus in 
dogs with Malassezia dermatitis and concurrent pyoderma. Another study, by Kumar et al (2002), 
reported successful treatments within a duration of 44 days using terbinafine at a dosage of 2.5 mg/kg 
q24h in combination with topical terbinafine 1% cream and selenium sulphide 2.5% shampoo. The 
duration of treatment for ketoconazole in the same study was less than half than that of terbinafine 
(Kumar et al., 2002). 
Berger et al (2012) reported adverse effects for terbinafine to be vomiting, anorexia, diarrhoea, 
excessive panting, and in one dog elevated hepatic enzymes. Rosales et al (2005) did not observe any 
adverse effects of terbinafine in their study. 
Topical therapy 
Topical therapy can be used as a sole therapy or combined with systemic treatment options (Mueller et 
al., 2012). Topical therapy solely is often curative in the treatment of superficial Malassezia infections 
and might be especially effective for breeds with short coats or areas of focal alopecia (Miller et al., 
2013a). It may also be the most cost effective and safest treatment option in regards of possible 
adverse side effects (Nuttall, 2012). Agents are available in several topical formulations including 
shampoos, rinses, lotions, solutions, gels, creams and ointments (Miller et al., 2013c). Type of 
formulation might also influence the efficacy of a product. This was illustrated in the study by Stroh et 
al (2010) in which the shampoo vehicle was as effective in reducing superficial bacterial counts as the 
shampoo containing the active agents chlorhexidine and phytosphingosine.  
Therapies available and evaluated in vivo includes chlorhexidine, miconazole, a combination of 
chlorhexidine and miconazole, piroctone olamine, selenium sulphide, a herbal formulation and 
climbazole (Bond et al., 1995b; Cavana et al., 2015a, 2015b; Jasmin et al., 2003; Lloyd and Lamport, 
1999; Marsella et al., 2000; Maynard et al., 2011; Nardoni et al., 2014; Rème et al., 2003) 
A number of in vivo studies report the topical use of enilconazole (Carlotti and Laffort-Dassot, 1996; 
Mueller et al., 2012; Negre et al., 2009), ketoconazole (Kumar et al., 2002; Sai Prasanna et al., 2006) 
and terbinafine (Kumar et al., 2002) although always in combination with systemic antimycotic 
therapy.  
Chlorhexidine 
Several in vitro studies reports chlorhexidine products of 2-4% concentration to have low minimum 
fungicidal concentration for isolates of Malassezia pachydermatis (Lloyd and Lamport, 1999; Uri et 
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al., 2016; Young et al., 2012). Loyd and Lamport (1999) reported that products with lower 
concentrations needed more time to eliminate the Malassezia organisms, although the product of 3% 
chlorhexidine tested was more efficient than the 4% chlorhexidine product in this in vitro study, in 
which chlorhexidine gluconate was used. The authors suggested that the formulation other than the 
chlorhexidine concentration was important for the efficacy of the product. In another in vitro study, 
Uri et al (2016) reports a lower minimum fungicidal concentration (MFC) for a 4% chlorhexidine 
gluconate product versus 3% chlorhexidine digluconate. The authors suggested that this difference 
might not only be due to the concentration of chlorhexidine, as additional ingredients varied in the 
products tested. In the 4% chlorhexidine product an additive effect of isopropyl alcohol was possible, 
whereas the 3% product reported as less effective also contained 0.5% climbazole and 
phytosphingosine.   
The in vivo effect of chlorhexidine was studied by Maynard et al (2011) in a prospective, controlled, 
randomized, single blinded study. The trial compared the efficacy of a 3% chlorhexidine shampoo 
with a control shampoo containing 2% chlorhexidine and 2% miconazole. The trial included 54 dogs 
that were evaluated until cytological recovery or a maximum of six weeks. Treatment regime for the 
chlorhexidine shampoo was three times weekly for two weeks, then twice weekly for two weeks and 
lastly once weekly for two weeks. The control product was applied twice weekly. Maynard et al 
(2011) based the evaluation of treatment efficacy primarily on reduction of Malassezia counts and 
secondary on reduction of  twelve clinical parameters. Treatment with both products resulted in a large 
reduction of Malassezia count and reduction of all clinical parameters measured. Most cases recovered 
within four weeks of treatment and a good clinical response was reported in 86.4-90.6% of the cases 
(Maynard et al., 2011). None of the efficacy parameters measured differed significantly between the 
two products tested. Maynard et al (2011) reported treatment failure for one dog in each product 
group.  
Jasmin et al (2003) found a 3% chlorhexidine shampoo to be efficient in the treatment of Malassezia 
dermatitis. The study included 28 dogs and shampoo was applied twice weekly for three weeks. The 
treatment resulted in a statistically significant reduction of clinical lesions, pruritus and Malassezia 
population scores. In fact, Malassezia population scores were reduced by more than 97% and 93% of 
the dogs had a yeast score regarded as normal flora at the end of the trial (Jasmin et al., 2003). 
Jasmin et al (2003) did not observe any adverse side effects in their trial using a 3% chlorhexidine 
shampoo. However, transient adverse effects in 4 of 31 cases for a shampoo containing 3% 
chlorhexidine was reported by Maynard et al (2011). The adverse effects reported were acute 
pododermatitis in one forelimb, exfoliation and scaling of the skin and increased pruritus. In addition, 
contact allergy to chlorhexidine have been reported in humans (Opstrup et al., 2016; Toholka and 
Nixon, 2013).  
Chlorhexidine/Miconazole   
A randomized, double blinded study set up by Bond et al (1995b) evaluated the antifungal efficacy of 
a shampoo containing 2% chlorhexidine and 2% miconazole for treatment of seborrhoeic dermatitis 
associated with Malassezia pachydermatis. The study included 33 dogs and the efficacy of 2% 
chlorhexidine and 2% miconazole shampoo was compared to a 0.25% selenium sulphide shampoo. 
Shampoos were applied at a three day interval during three weeks. Bond et al (1995b) reported a 
statistically significant reduction of both clinical lesions and Malassezia population counts for dogs 
treated with the 2%chlorhexidine and 2% miconazole shampoo. Compared to the selenium sulphide 
shampoo the chlorhexidine and miconazole shampoo showed a significantly greater reduction of 
pruritus, erythema, exudation, overall severity and Malassezia population counts. Bond et al (1995b) 
did not observe any adverse reactions.   
Maynard et al (2011) confirmed the good efficacy of a shampoo containing 2% chlorhexidine and 2% 
miconazole in the treatment of Malassezia dermatitis. In their study the shampoo significantly reduced 
Malassezia populations and clinical lesions. Cytological recovery was obtained within 28 days for a 
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majority of the cases and no adverse effect were reported for the treatment with combined 
chlorhexidine and miconazole shampoo (Maynard et al., 2011).  
Malassezia pachydermatis is highly susceptible to both chlorhexidine and miconazole as reported by 
several in vitro studies (Carrillo-Muñoz et al., 2013; Lyskova et al., 2007; Uri et al., 2016). Although 
Cafarchia et al (2012) reported the antifungal activity to be low for miconazole. 
Climbazole 
Based on in vitro data published by Schmidt (1997) climbazole has a good antifungal activity against 
Malassezia pachydermatis.    
The antifungal in vivo efficacy of a 2% climbazole shampoo was reported by Cavana et al (2015b) in a 
randomized study of healthy dogs. In the study the efficacy of the climbazole shampoo was compared 
to that of a physiological shampoo base without antifungal properties. Shampoos were applied once 
weekly for two weeks. The climbazole shampoo showed significant reduction of Malassezia 
population sizes already after one application and remained significantly decreased fifteen days after 
the second application of the climbazole shampoo. Cavana et al (2015b) did not observe any 
significant reductions of Malassezia populations in dogs treated with the physiological shampoo. No 
adverse effects were observed  for the 2% climbazole shampoo during the study period (Cavana et al., 
2015b). 
In another study Cavana et al (2015a) evaluated the in vivo activity of wet wipes, containing 
chlorhexidine 0.3%, climbazole 0.5% and Tris-EDTA, against Malassezia pachydermatis. The study 
included five healthy dogs with cutaneous elevated Malassezia populations. Using a split body 
protocol, wipes were applies once or twice daily for three consecutive days. Significant reduction of 
Malassezia counts was obtained 30 min after the first application and remained significantly reduced, 
compared to the initial count, seven days after the last application. There was no difference in results 
between the application once or twice daily (Cavana et al., 2015a). Transient erythema and pruritus at 
the application site was noted in one of the dogs. 
Essential oils 
The efficacy of a herbal formulation consistent of essential oils as sole treatment of Malassezia 
dermatitis was studied by Nardoni et al (2014). The formulation contained: Citrus aurantium 1%, 
Lavandula officinalis 1%, Origanum vulgare 0.5%, Origanum majorana, 0.5%, Mentha piperita 0.5% 
and Helichrysum italicum var. italicum 0.5%. Nardoni et al (2014) set up a prospective, randomized, 
single blinded study in which 35 dogs were divided into three groups.  Five dogs were left untreated 
and the remaining received one of the following treatments: topical herbal formulation applied twice 
daily for one month or treatment for three weeks with a combination of systemic ketoconazole 
10mg/kg q24h and topical 2% chlorhexidine twice a week. Based on evaluation performed thirty days 
after initiated treatment Nardoni et al (2014) reported significant reduction of clinical lesions and 
Malassezia population size for both treated groups but not for the untreated group. The efficacy did 
not differ between the two groups receiving treatment although there were two dogs that did not show 
a good clinical response, both belonging to the group treated with the herbal formulation. Recurrence 
of clinical signs at 180 days post initiation of treatment was not observed for the group treated with the 
herbal formulation but reported in the group treated with ketoconazole and chlorhexidine (Nardoni et 
al., 2014).  
In the same study, in vitro data revealed the active major composites of the herbal formulation to be 
thymol, carvacrol, p-cymene, 1,8-cineol, limonene and menthol; and the minimum inhibitory 
concentration for the product as a whole was reported to be low (Nardoni et al., 2014). Khosravi et al 
(2016) studied the effect of several essential oils in vitro and reported low minimum inhibitory 
concentrations for Zataria multiflora and Thymus kotschyanus. The main constituent of these oils were 
thymol and carvacrol which are both phenolic compounds. 
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Miconazole 
A randomized double blinded study evaluated the use of a 1% and 2% miconazole conditioner and 
controlled their efficacy against a placebo vehicle conditioner (Marsella et al., 2000). The study 
included 18 dogs divided into three groups, each group was shampooed once weekly with a 
nonmedicated shampoo and conditioner was then applied three times weekly for two weeks and then 
twice weekly for an additional two weeks. Marsella et al (2000) reported that Malassezia population 
size had decreased significantly for both two groups treated with miconazole after two weeks 
treatment, while the dogs treated with the vehicle had significantly higher counts at that point. 
However, by the end of the treatment period all treatments regimes had significantly reduced the 
Malassezia population sizes and there was no significant difference between any of the groups. All 
three treatment regimens also resulted in a significant reduction of erythema and pruritus at the end of 
the study period without any significant difference between the treatment groups at any point during 
the study (Marsella et al., 2000). In the study by Marsella et al (2000) eight dogs required further 
systemic treatment after the study period, out of which half had been treated with the vehicle product 
and the other half with one of the miconazole products.  
In vitro studies are inconclusive regarding the antifungal activity of miconazole, both high antifungal 
activity (Carrillo-Muñoz et al., 2013; Lyskova et al., 2007) and low antifungal activity is reported 
(Cafarchia et al., 2012).  
Piroctone olamine 
In a study by Rème et al (2003) a combination of piroctone olamine containing shampoo and lotion 
was evaluated. The study included 14 dogs with keratoseborrhoeic disorder and high Malassezia 
populations. Treatment regime consisted out of shampoo once weekly and lotion twice weekly for the 
duration of three weeks and resulted in a significant reduction of excoriations, keratoseborrhoeic 
disorder, erythema, pruritus and M. pachydermatis populations (Rème et al., 2003). Piroctone olamine 
have also been reported to reduce Malassezia pachydermatis populations on the skin of healthy dogs 
(Bourdeau et al., 2006). 
Selenium sulphide 
In a randomized, double blinded study 0.25% selenium sulphide shampoo was one of the treatments 
evaluated on dogs with seborrhoeic dermatitis associated with Malassezia pachydermatis (Bond et al., 
1995b). The dogs in the study were shampooed with selenium sulphide at three day intervals for three 
weeks which resulted in a statistically significant reduction of clinical manifestations and Malassezia 
pachydermatis populations for the dogs treated. Although six of the seventeen dogs treated with the 
selenium sulphide shampoo did not respond clinically and had persistently high Malassezia 
pachydermatis population counts (Bond et al., 1995b).  
Selenium sulphide 2,5% shampoo have been used successfully in combination with systemic treatment 
of itraconazole (Kumar et al., 2002; Sai Prasanna et al., 2006). It has also been reported in successful 
treatments combined with systemic and topical terbinafine (Kumar et al., 2002). Mason and Evans 
(1991) reported using selenium sulphide shampoo in combination with systemic ketoconazole and 
other topical agents. They argued that the keratolytic effect of selenium sulphide removes access 
keratin and thereby eliminates the yeast, although they did not recommend it to be used as the only 
acting agent in treatment of Malassezia dermatitis (Mason and Evans, 1991).  
In vitro  
Based on in vitro data reported by Young et al (2012) it was concluded by Mueller et al (2012) that  
treatment with acetic acid and boric acid or benzoyl peroxide may be useful in treatment of Malassezia 
dermatitis.  
Other agents reported to have good antifungal activity with low minimum inhibitory concentrations 
for Malassezia pachydermatis are numerous and include: amphotericin B, bifonazole, 
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ciclopiroxolamin, clotrimazole, econazole, ethyl lactate, nystatin, pimaricin, posaconazole  and 
voriconazole (Álvarez-Pérez et al., 2016; Brito et al., 2009; Lyskova et al., 2007; Schmidt, 1997; 
Young et al., 2012; Yurayart et al., 2013).  
 
Evidence based therapies 
In a systematic review based on in vivo studies of interventions for Malassezia dermatitis in canines 
Negre et al (2009) concluded that the only treatment options that fulfilled the criteria of being 
evidence based were:  
- Systemic treatment with ketoconazole 5-10 mg/kg q24h for 3 weeks OR itraconazole: 5 mg/kg 
q24h for 3 week 
- Topical treatment with 2% chlorhexidine in combination with 2% miconazole nitrate shampoo 
twice weekly for 3 weeks 
In a review by Mueller et al (2012), focusing on topical therapies for yeast and bacteria, the authors 
concluded that there is good evidence for the use of 2% chlorhexidine in combination with 2% 
miconazole for the treatment of cutaneous infections by Malassezia spp..  
There is also good evidence for the use of  3% chlorhexidine in shampoo formulation as a treatment of 
cutaneous Malassezia infections. This evidence is mainly based on the prospective, controlled, 
randomised, single-blinded study by Maynard et al (2011). Although the efficacy of chlorhexidine has 
also been reported in several other studies (Jasmin et al., 2003; Lloyd and Lamport, 1999; Uri et al., 
2016; Young et al., 2012).   
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BACKGROUND 
Hydrogen peroxide 
Hydrogen peroxide (H2O2) is an effective germicide widely used for antisepsis, disinfection and 
sterilization. In contact with organic tissue it decomposes into water and oxygen, making it safe for 
medical use and environmentally friendly (Block, 2001). The decomposition is fast in water solution 
but when stabilized in a cream formula of 1% hydrogen peroxide a slow decomposition is obtained 
thereby prolonging the effect (Christensen and Anehus, 1994; Mueller et al., 2012). Hydrogen 
peroxide has both antibacterial and antifungal activity, although the activity is greater against bacteria 
compared to yeast (Block, 2001). In contrast, Millers et al (2013c) graded hydrogen peroxide as a 
weak germicide and concluded that it was of limited use in treatment of skin disease in animals. 
Acting as an oxidant, hydrogen peroxide produces hydroxyl free radicals which damages lipids, 
proteins, DNA and other essential cell components (Block, 2001; McDonnell and Russell, 1999).  
Hydrogen peroxide occurs naturally in bodily tissues as a result of cellular metabolism (Block, 2001). 
Furthermore it plays an important part of early inflammatory defence response against bacteria in 
which the response includes release of hydrogen peroxide by phagocytising neutrophils (Block, 2001; 
Mueller et al., 2012). The enzymatic production of hydrogen peroxide is also reported to play an 
important role for the antimicrobial effects of honey (Feás et al., 2013; French et al., 2005; Miller et 
al., 2013c).  
The use of a 1% hydrogen peroxide cream for topical treatment has been reported safe and effective 
for both a human bacterial skin infection called impetigo contagiosa (Christensen and Anehus, 1994) 
and human acne vulgaris (Capizzi et al., 2004; Milani et al., 2003). In veterinary medicine a 1% 
hydrogen peroxide cream was reported to efficiently prevent bacterial colonization during wound 
healing in a randomized, blinded, controlled study in horses (Tóth et al., 2011).  
To the best of my knowledge neither in vitro nor in vivo data regarding the antifungal activity of 
hydrogen peroxide for Malassezia spp. has yet been reported. 
Crystavet® 
Crystavet® is an antimicrobial cream product with 1% hydrogen peroxide produced by Bioglan. The 
product was at the time of this study not yet commercially available. 
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AIM OF THE STUDY 
The purpose of this study was to, in a prospective, open, randomized, controlled study, evaluate the 
efficacy of a new topical product, Crystavet® (1% hydrogen peroxide, Bioglan, Malmö, Sweden), for 
the treatment of Malassezia overgrowth in dogs. Evaluation of treatment efficacy was primarily based 
on changes in mean Malassezia count obtained by cytology. Secondary evaluation criteria were 
changes in clinical skin lesion score, pruritus score and Malassezia count based on quantitative 
culture.   
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MATERIAL AND METHODS 
Literature review  
With the use of the databases PubMed, Google Scholar, Science Direct, Web of Science, Wiley Online 
Library and Primo, literature was searched regarding Malassezia spp. and Malassezia dermatitis in 
canines. Included search words were: Malassezia, Malassezia dermatitis, yeast dermatitis, canine*, 
dog* skin, Malassezia isolates*, treatment*, therapy, diagnose*, hydrogen peroxide etc. Reference list 
in articles and books found relevant were also used in the search.  
Information was gathered April-December 2016. Articles and texts were restricted to publications in 
English and Swedish.  
Clinical study  
Study design 
The study was set up as a prospective, open, randomized, controlled study using a split-body protocol. 
The study took place during 2016, divided into two study periods: May and September/October.   
Privately owned dogs with Malassezia overgrowth was recruited through the University Animal 
Hospital, Uppsala, Sweden and the dermatology department at DjurAkuten AB, Stockholm, Sweden. 
The recruitment also included advertising in social media and e-mailing veterinary- and veterinary 
nurse students at the Swedish University of Agricultural Sciences.   
Inclusion criteria were:  
• Dogs presented with two or more anatomically distinct sites with an mean of ≥4 Malassezia 
yeast organisms per 10 microscopic fields at 1000 magnification 
• Signed informed owner consent form 
If the patient presented with more than three sites available for inclusion, the lesions with the highest 
average numbers of organisms were chosen for the study. 
Exclusion criteria were:  
• Treatment with systemic antimycotic substances or topical antimycotic substances on the skin 
site included in the study ≤10 days prior to enrolment and throughout the study period.  
• Adverse reactions incompatible with continued treatment, after recording data. 
• Non-compliance to study protocol 
After signing an informed owner consent form, a clinical history was taken and a general physical 
exam was conducted. The study group was divided into two subgroups, based on prior treatments. 
Inclusion in subgroup A required that the patient had not initiated or changed any treatment, systemic 
or topical of, or adjacent to, area of inclusion, of any substances ≤28 days prior to entry or throughout 
the study period. Patients that did not fulfil this criteria were included in subgroup B.  
The general pruritus pre-treatment was estimated by the patient’s owner using a validated pruritus 
visual analogue scale (PVAS). Cytology was performed on clinical skin lesions and if compatible with 
inclusion criteria, contact plates were used to take samples for fungal culture from the chosen lesions. 
The skin at each site was assessed for clinical lesions using clinical lesion scoring.  
Patients were treated at home by the owner according to written and oral instructions given at start of 
the study period and the treatment was thus not blinded for the owner or the investigator. Each patient 
was used as their own control by treating the anatomically distinct lesion sites with either Crystavet® 
(1% hydrogen peroxide, Bioglan, Malmö, Sweden) 0.05 ml/cm2 twice daily or Trikem spray (4% 
chlorhexidine, Trikem AB, Klågerup, Sweden) 0.025 ml/cm2 twice daily for seven days . The choice 
of treatment for the lesions was randomized using a dice for the site with the highest average of 
Malassezia yeast organisms on cytology. The site with the second highest average of Malassezia yeast 
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organisms was then treated with the other treatment protocol. If possible, when more than two lesional 
sites were present and the owner complied, one randomized lesion was left untreated. 
Evaluation of the treatment was performed after seven days and included a short owner interview, a 
general physical examination and owner estimation of pruritus post-treatment using PVAS. The 
owners had been instructed to not treat the sites on the same day as the evaluation. Sampling for 
cytology and culture was performed and skin lesions were scored according to the same procedure as 
on the inclusion day. Cytological recovery post treatment was defined as a result of ≤0.2 mean 
Malassezia yeast organism on cytology. Any kind of side effect was recorded. The owners were given 
an evaluation form in which they were asked to evaluate treatment outcome, possible adverse effect, 
user friendliness of products and quality of instructions. Any kind of adverse effect was treated lege 
artis, after recording. 
Pruritus visual analogue scale, PVAS 
To assess the effect on pruritus, a pruritus visual analogue scale (PVAS) with descriptors was used, 
one pre- and one post-treatment. From the visual analogue scale a number between 0 and 10, 
representing the severity of pruritus, was calculated were 0 represented normal/no itching and 10 
extremely severe itching. The descriptors was translated into Swedish by K. Bergvall and based on the 
validated canine pruritus visual analogue scale (Hill et al., 2007; Rybníček et al., 2009).  
Cytology  
Cytology was performed with tape strip technique: using a clear acetate tape pressed to the skin once. 
The sample was stained with a drop of basophilic thiazine dye Hemacolor rapid staining kit (Merck 
KGaA, Darmstadt, Germany) and the mean of Malassezia yeast organisms per 10 oil immersion fields 
(HPF), under 1000 magnification was calculated.  
Fungal culturing 
Custom made contact plates were manufactured with modified Dixon’s 
medium (National veterinary institute, Uppsala, Sweden) in test tubes 
with a 13 mm diameter, see Figure 1. These were made in two separate 
batches for the different study periods: 2016-05-04 for May and 2016-
09-02 for September/October.  
Sampling of lesions for fungal culture was performed by lightly pressing 
the contact plates against the skin surface for 10 seconds. Within 12 hours after sampling the contact 
plates were cultured at 30°C+/-1°C for 4-5 days. Quantification of colonies was performed by 
manually counting colony forming units (CFU). For cultures of confluent growth on the contact plates 
the CFU was determined to be >100 CFU.  
Colonies from the contact plates were then cultured for species differentiation using agar plates of 
modified Dixon’s medium (National veterinary institute, Uppsala, Sweden) and Sabouraud’s medium 
(National veterinary institute, Uppsala, Sweden) at 30°C+/-1°C for 4-5 days. This process was 
overseen by a third party, to whom the cultures were blinded.  
• If pure culture and colony appearance corresponded with that of Malassezia pachydermatis on 
the contact plate, a colony was transferred to both modified Dixon’s medium and Sabouraud’s 
medium to confirm or exclude Malassezia pachydermatis.  
• If pure culture and colony appearance did not correspond with that of Malassezia 
pachydermatis on the contact plate but other fungal species was suspected, a colony was 
transferred to modified Dixon’s medium.  
• If cultures were of mixed species on the contact plates, pure culture was obtained by 
transferring a colony for each different fungal macroscopic appearance to modified Dixon’s 
Figure 1. Contact plate  
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medium separately. When pure culture was obtained, a colony was transferred to Sabouraud’s 
medium to confirm or exclude Malassezia pachydermatis.  
Suspected fungal colonies that could not be confirmed as Malassezia pachydermatis were analysed 
using Matrix Assisted Laser Desorption/Ionization Time of Flight mass spectrometry (MALDI-TOF 
MS, Bruker Daltonics Microflex, MALDI Biotyper, Bremen, Germany) performed at the National 
Veterinary Institute laboratory according to standard laboratory procedure. Growth of colonies with 
bacterial macroscopic appearance on the contact plates was noted but not cultured for species 
differentiation.  
Clinical lesion score 
Each lesional skin area included in the study was rated according to 11 clinical skin lesions including 
erythema, lichenification, hyperpigmentation, alopecia, papules, pustules, collarettes, crusts, 
excoriations, greasy seborrhoea and scaling. Lesion parameters were rated according to severity with 0 
representing no lesions, 1: mild, 2: moderate and 3 representing severe lesions. From this, a total 
clinical lesion score was calculated with a minimum value of 0 to a maximum value of 33. 
Statistical analysis 
Calculations were made using Microsoft Excel for PC and analyses performed using the statistical 
software Minitab version 17 for PC.  
Statistical analysis was performed on data obtained from cytology, clinical lesions score, PVAS and 
the owner evaluation form. A probability plot was used to determine whether data was para-metric or 
not. Further, Wilcoxon Signed Rank Test was used to analyse if there was a significant reduction of 
parameters post treatment compared to pre-treatment. Kruskal-Wallis test was used to evaluate if there 
was a difference between subgroup A and B for the cytology results obtained for Crystavet as well as 
between subgroup A and B for the reference product. The test was also used to evaluate whether there 
was any difference on inclusion day in mean yeast for cytology and clinical lesion scores between the 
sites included for the different therapies. Furthermore the test was applied on data from the owner 
evaluation form. For fungal culture data, the signtest was applied. For all tests, results with a P-value 
of < 0.05 were regarded as statistically significant.   
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RESULTS 
In total, ten dogs contributed with 22 anatomically distinct skin areas. In eight of the dogs, two skin 
sites were included and in the remaining two dogs, three skin sites were included. In the dogs with 
three skin sites, one site acted as an untreated control. All lesions were localized and anatomical areas 
included in the study were interdigital skin, lip folds and nose folds.  
The dogs included in the study were of the breeds: Nova Scotia duck tolling retriever, German 
shepherd, Labrador retriever, Pug, Beagle, Great Pyrenees and crossbreed. The age ranged from 1 year 
to 11 years with a mean of 4.5 and median of 3.6 years. Six of the dogs were female and four male, 
two of the males were neutered. Seven of the dogs fulfilled the criteria for subgroup A and the 
remaining three dogs were included in subgroup B. The treatments which placed the test 
subjects/patients in subgroup B were as follows: in one patient a single dose of carprofen seven days 
prior to inclusion, another patient had a 16 day treatment duration of cetirizine which had ceased eight 
days prior to inclusion day and had also received a single dose of imidacloprid and moxidectin 14 days 
prior to inclusion day. The third test subject in subgroup B underwent surgical removal of a 
mastocytoma on the day of inclusion, which included both anaesthesia and analgesia: cepromazin, 
metadon, haloperidol, atropine, prednisolone, propofol, isoflurane, and meloxicam followed by post-
operative carprofen. 
Six of the dogs had a history of diagnosed dermatitis and six dogs had a history of otitis externa. Two 
dogs were previously diagnosed with atopic dermatitis and four dogs were under ongoing 
investigations for suspected allergies. See Table 1 for details.  
Subject Previous diagnoses of dermatitis, otitis externa or allergy Ongoing investigation 
of allergy 
1 Malassezia overgrowth, otitis externa  ✔ 
2 Malassezia overgrowth mixed with pyoderma, otitis externa - 
3 - - 
4 Dermatitis (no cytology), multiple otitis externa ✔ 
5 Dermatitis (no cytology), otitis externa, atopic dermatitis - 
6 - - 
7 Otitis externa - 
8 Dermatitis (no cytology), multiple otitis externa  ✔ 
9 Malassezia overgrowth, otitis externa, atopic dermatitis ✔ 
10 Otitis externa - 
 
All dogs followed the study protocol and completed the study, none were lost to follow up or excluded 
during the study period.  
Pre-treatment observations 
Results include areas treated either with Crystavet or the reference product. Results from untreated 
areas are reported separately.  
Cytology   
The mean of Malassezia yeast organisms per 10 oil immersion/high power field (HPF), under 1000 
magnification at the time of inclusion is presented in Table 2.  
Table 1. Dermatological clinical history 
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Mean cytology results on the inclusion day did not differ significantly between the sites included for 
the different therapies (P=0.850). For subgroup A and B there was a statistical significant difference 
(P=0.017) in pre-treatment cytology data for Crystavet with a higher average of mean yeast for 
subgroup B. There was no statistical significant difference between subgroup A and B regarding pre-
treatment cytology data for the reference product (P=0.305). 
  Product  
 Crystavet  Reference 
Total  46.16 (28.35)  40.08 (25.20) 
Subgroup A 21.66 (20.70)  31.84 (23.9) 
Subgroup B 103.33 (60.40)  59.3 (59.5) 
 
Fungal culture 
Microorganisms were cultured on all contact plates and in 11 cultures Malassezia pachydermatis was 
confirmed. No other Malassezia spp. was found. Of the sites selected for treatment with Crystavet or 
reference product, five and six sites respectively were positive for Malazzezia.  The quantity of CFU 
for all M. pachydermatis positive cultures was >100 CFU. In addition, Candida albicans was 
confirmed in one of the samples with growth of Malassezia pachydermatis. This finding was recorded 
in a culture from interdigital skin.  
Clinical lesions 
On inclusion day the mean total lesion score was 3.9 and median 3, minimum total clinical lesion 
score noted was 1 and maximum 10. There was no statistical significance difference (P=0.789) for 
total lesion scores between sites included for the different therapies nor between subgroups within 
each treatment group of Crystavet (P=0.083) or the reference product (P=0.107). Erythema was noted 
in all sites included on inclusion day and the erythema score did not differ significantly between the 
sites included for the different therapies (P=0.490) or between subgroups within each therapy, 
Crystavet (P=0.602) and reference product (P=1.000).  
The patients’ mean and median pruritus visual analogue scale (PVAS) score was 3.28 and 3.6 
respectively. PVAS was noted at a minimum of 0.4 and maximum of 6.4. 
Post treatment observations 
Treatment duration varied from 5.5 days to 10 days. One dog was included for a prolonged treatment 
of 17 days total. Results obtained from that dog at the first revisit are included in the results reported 
here. Results of the prolonged treatment and from untreated areas are reported separately. No adverse 
side effects from either treatment was noted by the investigator.  
Cytology 
Malassezia populations were significantly reduced by both Crystavet (P=0.003) and the reference 
product (P=0.003). There was no statistical significance found between treatment efficacies of 
reducing the mean number of yeast organisms in absolute numbers (P=1.00) or expressed as reduction 
in percent (P=1.00). Mycological recovery based on cytology was obtained in eight out of ten areas 
treated with Crystavet and in seven out of ten areas treated with the reference product. Four of the sites 
that did not recover came from the same two test subjects and the one additional site for the reference 
product, came from a third test subject. The mean and median reduction of Malassezia yeast 
organisms per 10 oil immersion/ HPF, with 1000 magnification at post treatment evaluation is 
Table 2. Mean (median) Malassezia yeasts obtained by cytology at the time of inclusion 
for sites of each treatment group.   
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presented in Table 3. Pre- and post treatment cytology data for each site and treatment is illustrated in 
Figure 2. 
For treatment with Crystavet there was a significant difference in reduction of absolute numbers of 
yeast organisms when comparing subgroup A and B (P=0.017) but not when mean yeast reduction was 
expressed as percent (P=0.521). For the reference product there was no significant difference between 
subgroup A and B for either reduction in absolute numbers (P= 0.305) or reduction expressed as 
percent (P = 0.888). 
  Product  
 Crystavet  Reference 
Total -43,66 (-28.3)  -36.9 (-23) 
Total (%) -0.89 (-1)  -0.90 (-1) 
Subgroup A -18.1 (-19.4)  -28.03 (-22.1) 
Subgroup A (%) -0.84 (-1)  -0.89 (-1) 
Subgroup B -103.3 (-60.4)  -57.6 (-59.5) 
Subgroup B (%) -1 (-1)  -0.92 (-1) 
 
 
Fungal culture 
Reduction of Malassezia populations based on fungal culture was significant with both Crystavet 
(P=0.03125) and the reference product (P=0.03125). Complete mycological recovery was obtained in 
Table 3. Mean (median) reduction of Malassezia yeasts obtained by cytology at time of 
evaluation, presented as number of yeast organisms and percentage (%) for sites of each 
    
 
 
Table 4. Quantitative results of Malassezia populations from samples positive for M.pachydermatis 
post treatment. Fungal culture expressed as CFU and cytology as mean yeast organisms.  
Figure 2. Mean Malassezia population size showed for each site and treatment group pre- and post 
treatment with columns of same colour originating from the same test subject.  
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three of five previously positive cultures from the Crystavet group and four out of six for the reference 
product group. One area treated with Crystavet found negative on fungal culture pre-treatment was 
positive post treatment with growth of 3 CFU, the species was confirmed as M. pachydermatis. Of the 
samples that were negative for Malassezia on culture post treatment, two sites, belonging to the same 
test subject, had detectable Malassezia yeasts on cytology. For quantitative results of positive fungal 
cultures and correlation with cytology results see table 4.  
                             Malassezia population 
Sample Therapy Fungal culture   Cytology 
1 Crystavet 5  0 
2 Crystavet 3  0.1 
3 Crystavet 32  13.5 
4 Reference 5  5.1 
5 Reference 23  25.1 
 
Clinical lesions 
Reduction of total clinical lesion score was significant both for treatment with Crystavet (P=0.011) 
and the reference product (P=0.007). There was no significant difference in efficacy between products 
(P=0.789). Based on total clinical lesion score, two skin sites did not improve clinically using the 
reference product, nor did three sites for Crystavet. Out of those that had not improved clinically, two 
out of three treated with Crystavet and one out of two from the reference product group obtained 
complete mycological recovery based on cytology. The remaining two sites were from the same test 
subject.  
Reduction of erythema as a clinical lesion subscore was found to be significant for Crystavet 
(P=0.018) and the reference product (P=0.018). Improvement was seen in six out of ten sites for both 
treatments respectively. In the sites where erythema had not been reduced, the cytological recovery 
was complete in three sites treated with Crystavet and two sites treated with the reference product. 
There was no significant difference in the products’ efficacy of reducing erythema (P=0.789).  
The PVAS score was significantly reduced (P=0.008) post treatment, the reduction did not vary 
significantly between subgroup A and B (P=0.286). The PVAS was reduced by a mean of -0.96 and 
median of -0.8.  
Owner evaluation form 
Ten owners participated in the study, all of them filled out the owner evaluation form at the follow up 
appointment. In general owners commented that they had a good to moderately good experience using 
both therapies, although seven reported that the dog found the spray application of the reference 
product unpleasant. When asked to rate how easy the product was to use both products were rated as 
easy to use and there was no statistical significant difference between the products (P=0.291). 
Instructions on how to use the products was reported as easy to understand and there was no statistical 
difference between Crystavet and the RP (P=0.503).  
Owners were asked if they experienced a difference in the efficacy of the products. Six owners 
deemed the efficacy equal, one believed that the reference product was more efficient and remaining 
three owners thought that Crystavet had been more efficient. Owners did not report any adverse side 
effects.  
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Other observations 
Untreated control areas 
In two of the subjects included in the study, one area was left untreated. Both these dogs fulfilled the 
criteria for inclusion in subgroup A and areas included were both interdigital skin. In one of the test 
subjects cytology of the untreated area showed a decrease in mean Malassezia organisms from 31.1 to 
2.2 yeasts while culture was positive with a growth of >100 CFU on both pre and post treatment. For 
the same subject areas treated according to study protocol had responded with an elimination of 
Malassezia based on cytology for both therapies tested. Culture was also negative for M. 
pachydermatis in the area treated with the reference product but positive with 5 CFU for the area 
treated with Crystavet. The second test subject who had an untreated area, also showed a decrease of 
mean Malassezia yeasts post treatment in the area left untreated, from 13.5 to 1.4. Culture for the 
untreated area was positive for M. pachydermatis (>100 CFU) pre-treatment but negative post 
treatment. The areas that were treated in this test subject, were both negative on cytology and culture 
post treatment. Culture pre-treatment for these sites was negative for Malassezia, although growth of 
unknown yeast was noted with a quantity of >100 CFU. Total clinical lesion score, including the 
erythema score, did not change for either of the two untreated control areas during the study.  
Prolonged treatment of “non-responder” 
Out of the five different skin sites in which treatment according to the study protocol failed to reduce 
the cytology population size to ≤0.2 as a mean, two sites belonged to the same test subject. This dog 
was further included in the study to evaluate whether a prolonged treatment was efficient. In this 
patient both skin sites, which were interdigital skin, were still positive on cytology and culture for 
Malassezia spp. after an initial study period of 10 days, although all samples had reduced in 
population size. The treatment period was prolonged for another seven days, resulting in a treatment 
period of seventeen days total. After seventeen days of treatment, cytology and culture was still 
positive for Malassezia spp. at the site treated with Crystavet. The cytology showed a decrease in 
population size of Malassezia spp. from a mean of 46.9 to 3 yeasts, and culture from >100 CFU to 48 
CFU. The site treated with the reference product was negative on both cytology and culture after the 
prolonged treatment. Total clinical lesion score had not changed during the initial treatment period for 
either of the areas. After the prolonged treatment both areas had reduced the total clinical lesion score 
with one point respectively, this was represented by a reduction of erythema in both areas.   
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DISCUSSION 
As stated by both Mueller et al (2012) and Negre et al (2009) in vivo trials assessing the efficacy of 
various therapies available for the treatment of Malassezia overgrowth are sparse. In vivo trials of 
chlorhexidine, either combined with miconazole or solely, at a concentration of ≥2%, have reported 
the efficacy of chlorhexidine in reducing mycological as well as clinical parameters (Bond et al., 
1995b; Jasmin et al., 2003; Maynard et al., 2011). In vitro studies reporting chlorhexidine to have a 
low minimum fungicidal concentration for isolates of Malassezia pachydermatis further supports the 
fact that chlorhexidine has fungicidal properties (Lloyd and Lamport, 1999; Uri et al., 2016; Young et 
al., 2012). Based on this, a 4% chlorhexidine formulation was chosen as a reference product.  
The in vivo studies of chlorhexidine accounted for in the present study evaluated the efficacy of 
shampoo formulations at a concentration of ≥2%. In contrast, the reference product used in this study 
was a spray lotion containing 4% chlorhexidine. This spray lotion was chosen with the purpose of 
avoiding possible vehicle (detergent) effects of shampoo since the product to be evaluated, Crystavet, 
had a cream formulation. Shampoo vehicle has been suggested to reduce antimicrobial and clinical 
parameters (Marsella et al., 2000; Stroh et al., 2010). Furthermore, it was desirable that the reference 
product, much like the cream formulation of Crystavet, remained on the skin for a longer time to 
produce a “leave on” effect. Since a shampoo is rinsed off after application it would not have achieved 
the same effect.  
At the time of inclusion there was no significant difference between sites that were to be treated with 
the two topical agents in regards to both cytological and clinical parameters. The distribution of 
cytological and clinical findings in sites included for the different therapies might thereby be 
considered equally distributed. However, there was a significant difference for cytological data 
observed between subgroups within the sites to be treated with Crystavet, with a higher mean of yeast 
for subgroup B. A significant difference between these subgroups was also seen on post treatment 
cytology data regarding reduction of numbers of organisms, in which the mean was higher for 
subgroup B. This significance was not found when the cytological reduction was expressed in percent. 
These findings suggest that inclusion in subgroup A or B did not affect the cytological or clinical 
outcome of this study.  
Cytological recovery was not defined as zero detectable Malassezia yeasts since the normal micro 
flora of healthy canine skin includes Malassezia spp (Kennis et al., 1996; Miller et al., 2013a; Nuttall, 
2012). The criteria for cytological recovery defined as ≤0.2 mean Malassezia yeast per 10 oil 
immersion fields/HPF, under 1000 magnification, was previously used by Maynard et al (2011). This 
criterion meant that a maximum of two yeast organisms were allowed in samples that were reported as 
cytologically recovered. The criterion for negative fungal culture was determined as zero CFU since 
one CFU on a contact plate might be the result of several closely adjacent micro colonies or 
Malassezia organisms, as stated by Bond et al (1994). Since several studies report of positive culture 
samples being negative on cytology (Bensignor et al., 2002, 2002; Cafarchia et al., 2005; Machado et 
al., 2011) fungal culture might be a more sensitive diagnostic tool for detection of Malassezia 
organisms. However, mycological recovery in the present study was primarily based on data from 
cytology due to its practical and common use in research and clinical practice (Bond et al., 1995a; 
Cafarchia et al., 2005; Machado et al., 2011; Mason and Evans, 1991; Miller et al., 2013a; Nuttall, 
2012). In the present study, only one sample, taken post treatment, was positive on culture but 
negative on cytology.  
Both therapies evaluated in this study achieved a significant reduction of mycological data without a 
statistically significant difference in the results. Mycological recovery based on cytology was reported 
in 8 out of 10 areas treated with Crystavet and in 7 out of 10 areas treated with the reference product 
(RP). Two sites for each product that did not achieve cytological recovery, came from the same two 
test subjects. This suggests that the efficacy of reducing Malassezia yeasts is equal for the two 
therapies tested and that the failure of therapy in these sites might be dependent on environmental or 
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host related factors. In another test subject, treatment with Crystavet, but not treatment with the RP, 
led to cytological recovery. This may be coincidental or indicative of a higher efficacy of Crystavet. In 
contrast, the results of the test subject enrolled for prolonged treatment showed the opposite trend, 
since the site treated with the RP had recovered mycologically but not the site treated with Crystavet. 
No conclusions can be drawn from these findings, but it is possible that a larger study population 
would reveal a significant difference in antifungal efficacy between Crystavet and the RP.  
Treatment with both products resulted in a significant reduction of total clinical lesion scores and there 
was no significant difference in efficacy between the treatment options. The total clinical lesion score 
included both acute manifestations such as erythema and alopecia as well as the more chronic 
manifestations of hyperpigmentation and lichenification (Miller et al., 2013a; Nuttall, 2012). Since the 
maximum treatment period of ten days in this study was relatively short compared to other studies 
(Bond et al., 1995b; Jasmin et al., 2003; Marsella et al., 2000; Maynard et al., 2011; Nardoni et al., 
2014), all measured parameters may not have been able to present with a notable change within the 
study period. Reduction of lesions such as alopecia, lichenification and hyperpigmentation likely take 
longer than 10 days due to the complex nature of repair and regeneration of skin (epidermis, dermis 
and hair follicles), while the inflammatory response manifested by erythema changes faster (Zachary 
and McGavin, 2011). Therefore erythema was also analysed separately as a clinical lesion subscore. In 
addition, erythema was also the only clinical manifestation present in all the sites included for the 
study, which is similar to findings by Maynard et al (2011), who reported erythema to be the most 
frequent clinical observation in their study. Both products in the present study resulted in a significant 
reduction of erythema and there was no significant difference in efficacy between Crystavet and the 
RP. For both therapies the P-value for reduction of total clinical lesion score was lower than the P-
value for reduction of the erythema score exclusively, which suggests that the significant reduction of 
the total clinical lesion score was not only dependent on reduction of erythema. Reduction of erythema 
as well as pruritus are reported as important outcome parameters in several studies of agents found 
efficient for topical treatment of Malassezia overgrowth with concurrent cutaneous lesions (Bond et 
al., 1995b; Jasmin et al., 2003; Marsella et al., 2000; Maynard et al., 2011; Rème et al., 2003). When 
evaluating clinical parameters, Marsella et al (2000) evaluated reduction in erythema and pruritus 
exclusively, while other studies have included additional manifestations such as excoriations, greasy 
exudate, lichenification and hyperpigmentation as well as a score of lesion extent. It is highly relevant 
to include clinical signs in the outcome analysis since reduction of clinical parameters is important to 
verify the diagnose Malassezia dermatitis (Bond and Lloyd, 1997; Nuttall, 2012). Reduction of 
clinical manifestations, especially erythema, may also act as a control for the mycological data 
obtained. It can be assumed that if changes in mycological and clinical parameters correlate, the risk of 
a false positive reduction value for mycological data is lower than if solely mycological data is 
reduced. This is relevant since untreated controls in this study did not show any reduction of clinical 
signs, including erythema, even though the cytology data was reported as significantly reduced. Even 
though the untreated controls do provide some interesting results, it is important to remember that no 
statistics could be applied due to low sample size. Nonetheless, the reduction of Malassezia organisms 
in the untreated sites resulted in a mean Malassezia count below the limit of the inclusion criteria, 
although neither of the sites fulfilled the criteria for cytological recovery. This reduction of Malassezia 
organisms noted in the untreated controls indicates that reduction of Malassezia attributed to the effect 
of products in the treated sites might not be solely dependent on the treatment. Since both untreated 
control sites were interdigital skin areas, it is possible that this noted reduction might be due to owners 
unconsciously drying the paws more vigorously after receiving the diagnosis of Malassezia 
overgrowth. Another possible cause of reduction in the untreated control sites could be that the relief 
of host response in the treated sites resulted in a redirection of host defense mechanisms to the 
untreated sites. Any systemic antifungal effects of the topical products used is unlikely but cannot be 
excluded. There are several possible factors, other than the therapies tested, that might have affected 
the Malassezia population size and clinical lesions for both untreated and treated sites. These include 
both changes in microclimate such as humidity (Bond et al., 2004) and capabilities of the host defence, 
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possibly affected by underlying medical conditions and dermatoses (Bond and Lloyd, 1997, 1998; 
Mauldin et al., 1997; Nuttall, 2012; Plant et al., 1992). An underlying hypersensitivity for Malassezia 
spp., as seen in some dogs with atopic dermatitis may be especially relevant (Nuttall and Halliwell, 
2001). In this study two dogs included had previously been diagnosed with atopic dermatitis and four 
dogs were under clinical evaluation for allergies.  
Out of the samples taken pre-treatment, of which all were positive on cytology, 50-60% were positive 
for fungal culture of Malassezia spp. Negative cultures for Malassezia spp. might be due to 
overgrowth of other microbes (Cafarchia et al., 2005), low detection sensitivity of contact plates 
(Bensignor et al., 2002; Bond et al., 1994), residual active product post treatment or failure to correctly 
identify Malassezia spp. The technique used to identify Malassezia pachydermatis by culture on 
Sabouraud’s medium is widely used and reported in studies as well as textbooks (Bond et al., 1996; 
Bond and Lloyd, 1996; Gordon, 1979; Miller et al., 2013a; Nuttall, 2012) and should therefore not 
affect the results unless the isolated strains were lipid dependent (Gaitanis et al., 2012; Wu et al., 
2015). Detection of other Malassezia spp. was dependent on MALDI-TOF MS, which is reported to 
identify Malassezia yeast by 100% on genus level (Kolecka et al., 2014). However, it is possible that 
samples analysed by MALDI-TOF MS were not sufficiently pure cultured or that the isolate was not 
included in the database used as reference (Bagge. E., National Veterinary Institute, Sweden, personal 
communication, 2016). 
Other possible factors affecting the outcome of this study might be sources of error such as faulty 
handling of samples, poor sampling technique and contaminated dye solution. To prevent this, hands 
were disinfected, gloves were used before handling the samples and samples were transported in a 
special designed container to prevent contamination. Furthermore, sample technique was standardized 
and performed by the same investigator for all samples collected. To minimize risk of dye 
contamination, solutions used in the clinics are changed regularly and controlled once weekly. 
Noncompliance to study protocol could have affected the outcome of the study and it is possible that 
some noncompliance was not reported by owners but this is less likely as great attention was paid to 
this in interviews performed at post treatment follow-ups. To prevent noncompliance due to 
instructions being unclear or difficult to understand, the owners received both written and pictorial 
information as well as a demonstration by the investigator at point of inclusion. At follow-ups, owners 
reported the treatment instructions as easy to understand. The lack of blinding in this study might have 
led to bias influencing the results. The risk for bias would be higher for the clinical lesion scoring 
since this was based on the investigators subjective assessment of lesions changing gradually along a 
scale. This is in contrast to the mycological measures obtained, since they were quantified according 
to standardized techniques. Lack of blinding in the study also affects the results obtained by reducing 
power. Low intra-rater reliability may also be a source of error but any possible inter-test variability 
was avoided since the same investigator performed all sampling.  
A significant reduction of pruritus score was observed for the test subjects. However, this reduction 
was not specified for each therapy option since the collected data regarded the estimation of general 
pruritus and not separate for each site included. Due to the split-body protocol used in the study, 
estimations of pruritus for each site would have been required to apply data of reduced pruritus to 
outcome results. Owners were not asked to rate the pruritus for each separate site as they are only able 
to estimate general pruritus and cannot distinguish differences between focal areas (Bergvall. K., 
Swedish University of Agricultural Sciences, personal communication, 2016).   
Owners reported both products to be easy to use, although Crystavet cream formulation might be 
preferable since seven of the ten dogs found the spray application of the RP lotion unpleasant. No 
adverse side effects of either treatments were noted for the products tested, not by owners nor the 
investigator. In comparison, transient adverse reactions of chlorhexidine have been reported in dogs 
(Maynard et al., 2011) and chlorhexidine contact allergy in humans (Opstrup et al., 2016; Toholka and 
Nixon, 2013). 
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CONCLUSIONS 
The results of this prospective, open, randomized, controlled pilot study suggest that topical treatment 
with Crystavet (1% hydrogen peroxide) is an effective and safe alternative in the treatment of 
localized Malassezia overgrowth in dogs. The results also suggest that the antifungal efficacy of 1% 
hydrogen peroxide is similar to that of 4% chlorhexidine for Malassezia species. Further studies are 
needed to confirm these results and should include a larger sample size for both treated and untreated 
sites. Blinding of further studies is recommended to increase power of presented statistics.   
  
 29 
 
ACKNOWLEDGEMENTS  
Thank you to my supervisor Kerstin Bergvall for all practical help, advice and support. You are 
inspirational! Thank you Elisabeth Bagge for the support in the laboratory. Thank you to all 
owners intrusting me with their dogs and thank you Bioglan for sponsoring with products used for 
testing. Lastly I’d like to thank my friends and loved ones who helped with proofreading when I 
was blind to my own words and whom have been a great support during the process of writing 
this thesis. 
  
 30 
 
REFERENCES  
Álvarez-Pérez, S., García, M.E., Peláez, T., Blanco, J.L., 2016. Genotyping and antifungal 
susceptibility testing of multiple Malassezia pachydermatis isolates from otitis and dermatitis 
cases in pets: is it really worth the effort? Medical Mycology 54, 72–79. Available at 
doi:10.1093/mmy/myv070 
Bensignor, E., 2008. Oral itraconazole as a pulse therapy for the treatment of canine Malassezia 
dermatitis: a randomised, blinded, comparative trial. The European Journal of Companion 
Animal Practice 18, 69–72. 
Bensignor, E., Jankowski, F., Seewald, W., Touati, F., Deville, M., Guillot, J., 2002. Comparison of 
two sampling techniques to assess quantity and distribution of Malassezia yeasts on the skin of 
Basset Hounds. Veterinary Dermatology 13, 237–241. 
Berger, D.J., Lewis, T.P., Schick, A.E., Stone, R.T., 2012. Comparison of once-daily versus twice-
weekly terbinafine administration for the treatment of canine Malassezia dermatitis – a pilot 
study. Veterinary Dermatology 23, 418-e79. Available at doi:10.1111/j.1365-
3164.2012.01074.x 
Block, S.S., 2001. Peroxygen compounds, in: Block, S.S. (Ed.), Disinfection, Sterilization, and 
Preservation. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 185–204. 
Bond, R., Anthony, R. m., 1995. Characterization of markedly lipid-dependent Malassezia 
pachydermatis isolates from healthy dogs. Journal of Applied Bacteriology 78, 537–542. 
Available at doi:10.1111/j.1365-2672.1995.tb03096.x 
Bond, R., Collin, N.S., Lloyd, D.H., 1994. Use of contact plates for the quantitative culture of 
Malassezia pachydermatis from canine skin. Journal of Small Animal Practice 35, 68–72. 
Available at doi:10.1111/j.1748-5827.1994.tb02536.x 
Bond, R., Ferguson, E.A., Curtis, C.F., Craig, J.M., Lloyd, D.H., 1996. Factors associated with 
elevated cutaneous Malassezia p a chyderm a tis populations in dogs with Pruritic skin isease. 
Journal of Small Animal Practice 37, 103–107. Available at doi:10.1111/j.1748-
5827.1996.tb02353.x 
Bond, R., Lloyd, D. h., 1997. Skin and mucosal populations of Malassezia pachydermatis in healthy 
and seborrhoeic Basset Hounds. Veterinary Dermatology 8, 101–106. Available at 
doi:10.1046/j.1365-3164.1997.d01-4.x 
Bond, R., Lloyd, D.H., 1998. The relationship between population sizes of Malassezia pachydermatis 
in healthy dogs and in Basset Hounds with M. pachydermatis-associated seborrhoeic 
dermatitis and adherence to canine corneocytes in vitro, in: Kwochka, K.W., Willemse, T., 
Claudia von Tscharner (Eds.), Proceedings of the Third World Congress of Veterinary 
Dermatology, Edinburgh, 11-14th September, 1996, Advances in Veterinary Dermatology, 3. 
Butterworth-Heinemann, Oxford, pp. 283–289. 
Bond, R., Lloyd, D.H., 1996. Comparison of media and conditions of incubation for the quantitative 
culture of Malassezia pachydermatis from canine skin. Research in Veterinary Science 61, 
273–274. Available at doi:10.1016/S0034-5288(96)90078-8 
Bond, R., Lloyd, D.H., Plummer, J.M., 1995a. Evaluation of a detergent scrub technique for the 
quantitative culture of Malassezia pachydermatis from canine skin. Research in Veterinary 
Science 58, 133–137. 
Bond, R., Patterson-Kane, J.C., Lloyd, D.H., 2004. Clinical, histopathological and immunological 
effects of exposure of canine skin to Malassezia pachydermatis. Medical Mycology 42, 165–
175. Available at doi:10.1080/1369378032000141435 
Bond, R., Rose, J.F., Ellis, J.W., Lloyd, D.H., 1995b. Comparison of two shampoos for treatment of 
Malassezia pachydermatis-associated seborrhoeic dermatitis in basset hounds. Journal of 
Small Animal Practice 36, 99–104. Available at doi:10.1111/j.1748-5827.1995.tb02840.x 
Bond, R., Saijonmaa-Koulumies, L.E.M., Lloyd, D.H., 1995c. Population sizes and frequency of 
Malassezia pachydermatis at skin and mucosal sites on healthy dogs. Journal of Small Animal 
Practice 36, 147–150. Available at doi:10.1111/j.1748-5827.1995.tb02865.x 
Bourdeau, P., Blumstein, P., Marchand, A.-M., Gardey, L., Jasmin, P., Gatto, H., 2006. An in vivo 
procedure to evaluate antifungals agents on Malassezia pachydermatis in dogs: example with a 
piroctone olamine containing shampoo. Journal de Mycologie Médicale 16, 9–15. Available at 
doi:10.1016/j.mycmed.2006.01.005 
 31 
 
Brito, E.H.S., Fontenelle, R.O.S., Brilhante, R.S.N., Cordeiro, R.A., Monteiro, A.J., Sidrim, J.J.C., 
Rocha, M.F.G., 2009. The anatomical distribution and antimicrobial susceptibility of yeast 
species isolated from healthy dogs. The Veterinary Journal 182, 320–326. Available at 
doi:10.1016/j.tvjl.2008.07.001 
Cafarchia, C., Figueredo, L.A., Iatta, R., Montagna, M.T., Otranto, D., 2012. In vitro antifungal 
susceptibility of Malassezia pachydermatis from dogs with and without skin lesions. 
Veterinary Microbiology 155, 395–398. Available at doi:10.1016/j.vetmic.2011.09.008 
Cafarchia, C., Gallo, S., Romito, D., Capelli, G., Chermette, R., Guillot, J., Otranto, D., 2005. 
Frequency, body distribution, and population size of Malassezia species in healthy dogs and in 
dogs with localized cutaneous lesions. Journal of Veterinary Diagnostic Investigation 17, 
316–322. 
Cafarchia, C., Gasser, R.B., Latrofa, M.S., Parisi, A., Campbell, B.E., Otranto, D., 2008. Genetic 
variants of Malassezia pachydermatis from canine skin: body distribution and phospholipase 
activity. FEMS yeast research 8, 451–459. Available at doi:10.1111/j.1567-
1364.2008.00358.x 
Cafarchia, C., Latrofa, M.S., Figueredo, L.A., da Silva Machado, M.L., Ferreiro, L., Guillot, J., 
Boekhout, T., Otranto, D., 2011. Physiological and molecular characterization of atypical 
lipid-dependent Malassezia yeasts from a dog with skin lesions: adaptation to a new host? 
Medical Mycology 49, 365–374. Available at doi:10.3109/13693786.2010.531487 
Capizzi, R., Landi, F., Milani, M., Amerio, P., 2004. Skin tolerability and efficacy of combination 
therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with 
benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-
masked, controlled trial. The British Journal of Dermatology 151, 481–484. Available at 
doi:10.1111/j.1365-2133.2004.06067.x 
Carlotti, D., Laffort-Dassot, C., 1996. Dermatite à Malassezia chez le chien: étude bibliographique et 
rétrospective de 12 cas généralisés traités par des dérivés azolés. Pratique Médicale et 
Chirurgicale Des Animaux de Compagnie 1996, 297–307. 
Carrillo-Muñoz, A.J., Rojas, F., Tur-Tur, C., de los Ángeles Sosa, M., Diez, G.O., Espada, C.M., 
Payá, M.J., Giusiano, G., 2013. In vitro antifungal activity of topical and systemic antifungal 
drugs against Malassezia species. Mycoses 56, 571–575. Available at doi:10.1111/myc.12076 
Castellá, G., Hernández, J.J., Cabañes, F.J., 2005. Genetic typing of Malassezia pachydermatis from 
different domestic animals. Veterinary Microbiology 108, 291–296. Available at 
doi:10.1016/j.vetmic.2005.04.016 
Cavana, P., Peano, A., Petit, J.-Y., Bourdeau, P., Perrot, S., Bensignor, E., Guillot, J., 2015a. A pilot 
study of the efficacy of wipes containing chlorhexidine 0.3%, climbazole 0.5% and Tris-
EDTA to reduce Malassezia pachydermatis populations on canine skin. Veterinary 
Dermatology 26, 278-e61. Available at doi:10.1111/vde.12220 
Cavana, P., Petit, J.-Y., Perrot, S., Guechi, R., Marignac, G., Reynaud, K., Guillot, J., 2015b. Efficacy 
of a 2% climbazole shampoo for reducing Malassezia population sizes on the skin of naturally 
infected dogs. Journal de Mycologie Médicale 25, 268–273. Available at 
doi:10.1016/j.mycmed.2015.10.004 
Christensen, O.B., Anehus, S., 1994. Hydrogen peroxide cream: an alternative to topical antibiotics in 
the treatment of impetigo contagiosa. Acta Dermato-Venereologica 74, 460–462. 
Coutinho, S.D., Paula, C.R., 2000. Proteinase, phospholipase, hyaluronidase and chondroitin-
sulphatase production by Malassezia pachydermatis. Medical Mycology 38, 73–76. 
Dufait, R., 1975. Over enkele gevallen van dermatitis bij de hond, toegeschreven aan gistcellen (genus 
Candida en genus Pityrosporum). Vlaams Diergeneeskundig Tijdschrift 44, 92–94. 
Feás, X., Iglesias, A., Rodrigues, S., Estevinho, L.M., 2013. Effect of Erica sp. Honey against 
Microorganisms of Clinical Importance: Study of the Factors Underlying this Biological 
Activity. Molecules 18, 4233–4246. Available at doi:10.3390/molecules18044233 
French, V.M., Cooper, R.A., Molan, P.C., 2005. The antibacterial activity of honey against coagulase-
negative staphylococci. The Journal of Antimicrobial Chemotherapy 56, 228–231. Available 
at doi:10.1093/jac/dki193 
Gaitanis, G., Magiatis, P., Hantschke, M., Bassukas, I.D., Velegraki, A., 2012. The Malassezia Genus 
in Skin and Systemic Diseases. Clinical Microbiology Reviews 25, 106–141. Available at 
doi:10.1128/CMR.00021-11 
 32 
 
Gordon, M.A., 1979. Malassezia Pityrosporum pachydermatis (Weidman) Dodge 1935. Sabouraudia 
17, 305–309. Available at doi:10.1080/00362177985380451 
Grooters, A.M., Taboada, J., 2003. Update on antifungal therapy. Veterinary Clinics of North 
America: Small Animal Practice 33, 749–758. Available at doi:10.1016/S0195-
5616(03)00038-X 
Gupta, A. k., Kohli, Y., Li, A., Faergemann, J., Summerbell, R. c., 2000. In vitro susceptibility of the 
seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. British 
Journal of Dermatology 142, 758–765. Available at doi:10.1046/j.1365-2133.2000.03294.x 
Hensel, P., Santoro, D., Favrot, C., Hill, P., Griffin, C., 2015. Canine atopic dermatitis: detailed 
guidelines for diagnosis and allergen identification. BMC veterinary research 11, 196. 
Available at doi:10.1186/s12917-015-0515-5 
Hill, P.B., Lau, P., Rybnicek, J., 2007. Development of an owner-assessed scale to measure the 
severity of pruritus in dogs. Veterinary Dermatology 18, 301–308. Available at 
doi:10.1111/j.1365-3164.2007.00616.x 
Jasmin, P., Schroeder, H., Briggs, M., Last, R., Sanquer, A., 2003. Assessment of the efficacy of a 3% 
chlorhexidine shampoo in the control of elevated cutaneous Malassezia populations and 
associated clinical signs (Malassezia dermatitis) in dogs, in: Proceedings of the 19th Annual 
Congress of the ESVD ECVD, Tenerife. 
Kennis, R.A., Rosser, E.J., Olivier, N.B., Walker, R.W., 1996. Quantity and distribution of Malassezia 
organisms on the skin of clinically normal dogs. Journal of the American Veterinary Medical 
Association 208, 1048–1051. 
Khosravi, A.R., Shokri, H., Fahimirad, S., 2016. Efficacy of medicinal essential oils against 
pathogenic Malassezia sp. isolates. Journal de Mycologie Médicale 26, 28–34. Available at 
doi:10.1016/j.mycmed.2015.10.012 
Koch, S.N., Torres, S.M.F., Plumb, D.C., 2012. Canine and Feline Dermatology Drug Handbook. John 
Wiley & Sons. 
Kolecka, A., Khayhan, K., Arabatzis, M., Velegraki, A., Kostrzewa, M., Andersson, A., Scheynius, 
A., Cafarchia, C., Iatta, R., Montagna, M. t., Youngchim, S., Cabañes, F. j., Hoopman, P., 
Kraak, B., Groenewald, M., Boekhout, T., 2014. Efficient identification of Malassezia yeasts 
by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF 
MS). British Journal of Dermatology 170, 332–341. Available at doi:10.1111/bjd.12680 
Kumar, A., Singh, K., Sharma, A., 2002. Treatment of dermatitis in dogs associated with Malassezia 
pachydermatis. Indian Veterinary Journal 730–732. 
Läkemedelsindustriföreningen, 2014. Canizol vet. FASS Djurläkemedel. 
Lautert, C., Ferreiro, L., Jesus, F.P.K., Zanette, R.A., Mahl, D.L., Alves, S.H., Santurio, J.M., 2011. 
Enzymatic characterization of Malassezia pachydermatis isolates from dogs. African Journal 
of Microbiology Research 5, 2986–2990. Available at doi:10.5897/AJMR11.714 
Lloyd, D.H., Lamport, A.I., 1999. Activity of chlorhexidine shampoos in vitro against Staphylococcus 
intermedius, Pseudomonas aeruginosa and Malassezia pachydermatis. Veterinary Record 144, 
536–537. 
Lyskova, P., Vydrzalova, M., Mazurova, J., 2007. Identification and Antimicrobial Susceptibility of 
Bacteria and Yeasts Isolated from Healthy Dogs and Dogs with Otitis Externa. Journal of 
Veterinary Medicine 54, 559–563. Available at doi:10.1111/j.1439-0442.2007.00996.x 
Machado, M.L.S., Cafarchia, C., Otranto, D., Ferreira, R.R., Bianchi, S.P., Latrofa, M.S., Parisi, A., 
Ferreiro, L., 2010. Genetic variability and phospholipase production of Malassezia 
pachydermatis isolated from dogs with diverse grades of skin lesions. Medical Mycology 48, 
889–892. Available at doi:10.3109/13693780903532080 
Machado, M.L.S., Ferreiro, L., Ferreira, R.R., Corbellini, L.G., Deville, M., Berthelemy, M., Guillot, 
J., 2011. Malassezia dermatitis in dogs in Brazil: diagnosis, evaluation of clinical signs and 
molecular identification. Veterinary Dermatology 22, 46–52. Available at doi:10.1111/j.1365-
3164.2010.00909.x 
Marsella, R., Nicklin, C.E., Nerbonne, J., 2000. Double-blind, placebo-controlled study to evaluate 
two miconazole conditioners for the treatment of Malassezia dermatitis in dogs. Veterinary 
Therapeutics: Research in Applied Veterinary Medicine 1, 141–149. 
Mason, K.V., Evans, A.G., 1991. Dermatitis associated with Malassezia pachydermatis in 11 dogs. 
The Journal of the American Animal Hospital Association 27, 13–20. 
 33 
 
Mathieson, I., Fixter, L.M., Little, C.J.L., 1998. Enzymatic activity of Malassezia pachydermatis, in: 
Kwochka, K.W., Willemse, T., Tscharner, C. von (Eds.), Proceedings of the Third World 
Congress of Veterinary Dermatology, Edinburgh, 11-14th September, 1996, Advances in 
Veterinary Dermatology, 3. Butterworth-Heinemann, Oxford, pp. 532–533. 
Mauldin, E.A., Scott, D.W., Miller, W.H., Smith, C.A., 1997. Malassezia dermatitis in the dog: a 
retrospective histopathological and immunopathological study of 86 cases (1990–95). 
Veterinary Dermatology 8, 191–202. Available at doi:10.1046/j.1365-3164.1997.d01-15.x 
Maynard, L., Rème, C.A., Viaud, S., 2011. Comparison of two shampoos for the treatment of canine 
Malassezia dermatitis: a randomised controlled trial. Journal of Small Animal Practice 52, 
566–572. Available at doi:10.1111/j.1748-5827.2011.01124.x 
McDonnell, G., Russell, A.D., 1999. Antiseptics and Disinfectants: Activity, Action, and Resistance. 
Clinical Microbiology Reviews 12, 147–179. 
Milani, M., Bigardi, A., Zavattarelli, M., 2003. Efficacy and safety of stabilised hydrogen peroxide 
cream (Crystacide) in mild-to-moderate acne vulgaris: a randomised, controlled trial versus 
benzoyl peroxide gel. Current Medical Research and Opinion 19, 135–138. Available at 
doi:10.1185/030079902125001523 
Miller, W.H., Griffin, C.E., Campbell, K.L., 2013a. Fungal and Algal Skin Diseases, in: Muller and 
Kirk’s Small Animal Dermatology. Elsevier Mosby, St. Louis, Mo. 
Miller, W.H., Griffin, C.E., Campbell, K.L., 2013b. Diseases of Eyelids, Claws, Anals Sacs, and Ears, 
in: Muller and Kirk’s Small Animal Dermatology. Elsevier Mosby, St. Louis, Mo., pp. 724–
773. 
Miller, W.H., Griffin, C.E., Campbell, K.L., 2013c. Dermatologic Therapy, in: Muller and Kirk’s 
Small Animal Dermatology. Elsevier Mosby, St. Louis, Mo., pp. 108–222. 
Mobley, D., Meyer, D.J., 1994. A dermatitis associated with Malassezia in kenneled dogs. Veterinary 
medicine 89, 520–523. 
Mueller, R.S., Bergvall, K., Bensignor, E., Bond, R., 2012. A review of topical therapy for skin 
infections with bacteria and yeast. Veterinary Dermatology 23, 330-e62. Available at 
doi:10.1111/j.1365-3164.2012.01057.x 
Nardoni, S., Dini, M., Taccini, F., Mancianti, F., 2007. Occurrence, distribution and population size of 
Malassezia pachydermatis on skin and mucosae of atopic dogs. Veterinary Microbiology 122, 
172–177. Available at doi:10.1016/j.vetmic.2006.12.023 
Nardoni, S., Mancianti, F., Corazza, M., Rum, A., 2004. Occurrence of Malassezia species in healthy 
and dermatologically diseased dogs. Mycopathologia 157, 383–388. Available at 
doi:10.1023/B:MYCO.0000030416.36743.dd 
Nardoni, S., Mugnaini, L., Pistelli, L., Leonardi, M., Sanna, V., Perrucci, S., Pisseri, F., Mancianti, F., 
2014. Clinical and mycological evaluation of an herbal antifungal formulation in canine 
Malassezia dermatitis. Journal De Mycologie Medicale 24, 234–240. Available at 
doi:10.1016/j.mycmed.2014.02.005 
Negre, A., Bensignor, E., Guillot, J., 2009. Evidence-based veterinary dermatology: a systematic 
review of interventions for Malassezia dermatitis in dogs. Veterinary. Dermatology. 20, 1–12. 
Available at doi:10.1111/j.1365-3164.2008.00721.x 
Nijima, M., Kano, R., Nagata, M., Hasegawa, A., Kamata, H., 2011. An azole-resistant isolate of 
Malassezia pachydermatis. Veterinary Microbiology 149, 288–290. Available at 
doi:10.1016/j.vetmic.2010.10.010 
Nuttall, T., 2012. Malassezia dermatitis, in: Jackson, H., Marsella, R. (Eds.), BSAVA Manual of 
Canine and Feline Dermatology. British Small Animal Veterinary Association, Gloucester, pp. 
198–205. 
Nuttall, T.J., Halliwell, R.E.W., 2001. Serum antibodies to Malassezia yeasts in canine atopic 
dermatitis. Veterinary Dermatology 12, 327–332. Available at doi:10.1046/j.0959-
4493.2001.00261.x 
Opstrup, M.S., Johansen, J.D., Zachariae, C., Garvey, L.H., 2016. Contact allergy to chlorhexidine in a 
tertiary dermatology clinic in Denmark. Contact Dermatitis 74, 29–36. Available at 
doi:10.1111/cod.12487 
Pinchbeck, L.R., Hillier, A., Kowalski, J.J., Kwochka, K.W., 2002. Comparison of pulse 
administration versus once daily administration of itraconazole for the treatment of Malassezia 
 34 
 
pachydermatis dermatitis and otitis in dogs. Journal of the American Veterinary Medical 
Association 220, 1807–1812. Available at doi:10.2460/javma.2002.220.1807 
Plant, J., Rosenkrantz, W., Griffin, C., 1992. Factors associated with and prevalence of high 
Malassezia pachydermatis numbers on dog skin. Journal of the American Veterinary Medical 
Association 201, 879–882. 
Prado, M.R., Brilhante, R.S.N., Cordeiro, R.A., Monteiro, A.J., Sidrim, J.J.C., Rocha, M.F.G., 2008. 
Frequency of yeasts and dermatophytes from healthy and diseased dogs. Journal of Veterinary 
Diagnostic Investigation: Official Publication of the American Association of Veterinary 
Laboratory Diagnosticians, Inc 20, 197–202. Available at doi:10.1177/104063870802000208 
Prado, M.R., Brito, E.H.S., Girão, M.D., Monteiro, A.J., Sidrim, J.J.C., Rocha, M.F.G., 2004. Higher 
incidence of Malassezia pachydermatis in the eyes of dogs with corneal ulcer than in healthy 
dogs. Veterinary Microbiology 100, 115–120. Available at doi:10.1016/j.vetmic.2003.12.011 
Puig, L., Castellá, G., Cabañes, F.J., 2016. Cryptic Diversity of Malassezia pachydermatis from 
Healthy and Diseased Domestic Animals. Mycopathologia 181, 681–688. Available at 
doi:10.1007/s11046-016-0026-3 
Raabe, P., Mayser, P., Weiß, R., 1998. Demonstration of Malassezia furfur and M. sympodialis 
together with M. pachydermatis in veterinary specimens: Nachweis von Malassezia furfur und 
M. sympodialis in veterinärmedizinischem Untersuchungsgut. Mycoses 41, 493–500. 
Available at doi:10.1111/j.1439-0507.1998.tb00712.x 
Rème, C., Cadot, P., Holzapfel, G., Jasmin, P., 2003. Efficacy of combined topical therapy with 
keratoregulating shampoo and lotion in the management of keratoseborrhoeic disorders 
associated with Malassezia proliferation in dogs. Veterinary Dermatology 14, 264. 
Rosales, M.S., Marsella, R., Kunkle, G., Harris, B.L., Nicklin, C.F., Lopez, J., 2005. Comparison of 
the clinical efficacy of oral terbinafine and ketoconazole combined with cephalexin in the 
treatment of Malassezia dermatitis in dogs – a pilot study. Veterinary Dermatology 16, 171–
176. Available at doi:10.1111/j.1365-3164.2005.00455.x 
Rybníček, J., Lau-Gillard, P.J., Harvey, R., Hill, P.B., 2009. Further validation of a pruritus severity 
scale for use in dogs. Veterinary Dermatology 20, 115–122. Available at doi:10.1111/j.1365-
3164.2008.00728.x 
Sai Prasanna, J., Madhavi Latha, S., Satish Kumar, K., 2006. Therapeutic studies on seborrheic 
dermatitis in dogs associated with Malassezia pachydermatis. Indian Veterinary Journal 83, 
162–164. 
Schmidt, A., 1997. In vitro Activity of Climbazole, Clotrimazole and Silver-sulphadiazine against 
Isolates of Malassezia pachydermatis. Journal of Veterinary Medicine 44, 193–197. Available 
at doi:10.1111/j.1439-0450.1997.tb00964.x 
Scott, D.W., 1992. Bacteria and yeast on the surface and within non-inflamed hair follicles of skin 
biopsies from dogs with non-neoplastic dermatoses. The Cornell Veterinarian 82, 379–386. 
Sickafoose, L., Hosgood, G., Snook, T., Westermeyer, R.R., Merchant, S.R., others, 2010. A 
noninferiority clinical trial comparing fluconazole and ketoconazole in combination with 
cephalexin for the treatment of dogs with Malassezia dermatitis. Veterinary Therapeutics 11, 
E1-13. 
Stroh, A., Werckenthin, C., Luis, C.S., Mueller, R.S., 2010. Influence of a phytosphingosine-
containing chlorhexidine shampoo on superficial bacterial counts and bacterial adherence to 
canine keratinocytes. Veterinary Microbiology 141, 190–193. Available at 
doi:10.1016/j.vetmic.2009.08.018 
Toholka, R., Nixon, R., 2013. Allergic contact dermatitis to chlorhexidine. Australasian Journal of 
Dermatology 54, 303–306. Available at doi:10.1111/ajd.12087 
Tóth, T., Broström, H., Båverud, V., Emanuelson, U., Bagge, E., Karlsson, T., Bergvall, K., 2011. 
Evaluation of LHP® (1% hydrogen peroxide) cream versus petrolatum and untreated controls 
in open wounds in healthy horses: a randomized, blinded control study. Acta Veterinaria 
Scandinavica 53, 45. Available at doi:10.1186/1751-0147-53-45 
Uchida, Y., Mizutani, M., Kubo, T., Nakade, T., Otomo, K., 1992. Otitis externa induced with 
Malassezia pachydermatis in dogs and the efficacy of pimaricin. The Journal of Veterinary 
Medical Science 54, 611–614. 
 35 
 
Uri, M., Buckley, L.M., Marriage, L., McEwan, N., Schmidt, V.M., 2016. A pilot study comparing in 
vitro efficacy of topical preparations against veterinary pathogens. Veterinary Dermatology 
27, 152-e39. Available at doi:10.1111/vde.12306 
Wagner, R., Schadler, S., 2000. Qualitative study of Malassezia species colonisation in young puppies. 
Veterinary Record 147, 192–194. Available at doi:10.1136/vr.147.7.192 
White, S.D., Bourdeau, P., Blumstein, P., Ibish, C., Scott, K.V., Salman, M.D., Chapman, P.L., 1998. 
Comparison via cytology and culture of carriage of Malassezia pachydermatis in atopic and 
healthy dogs, in: Kwochka, K.W., Willemse, T., von Tscharner, C. (Eds.), Proceedings of the 
Third World Congress of Veterinary Dermatology, Edinburgh, 11-14th September, 1996, 
Advances in Veterinary Dermatology, 3. Butterworth-Heinemann, Oxford, p. s 291-298. 
Wu, G., Zhao, H., Li, C., Rajapakse, M.P., Wong, W.C., Xu, J., Saunders, C.W., Reeder, N.L., 
Reilman, R.A., Scheynius, A., Sun, S., Billmyre, B.R., Li, W., Averette, A.F., Mieczkowski, 
P., Heitman, J., Theelen, B., Schröder, M.S., Sessions, P.F.D., Butler, G., Maurer-Stroh, S., 
Boekhout, T., Nagarajan, N., Jr, T.L.D., 2015. Genus-Wide Comparative Genomics of 
Malassezia Delineates Its Phylogeny, Physiology, and Niche Adaptation on Human Skin. 
PLOS Genetics 11, e1005614. Available at doi:10.1371/journal.pgen.1005614 
Young, R., Buckley, L., McEwan, N., Nuttall, T., 2012. Comparative in vitro efficacy of antimicrobial 
shampoos: a pilot study. Veterinary Dermatology 23, 36-e8. Available at doi:10.1111/j.1365-
3164.2011.01002.x 
Yurayart, C., Nuchnoul, N., Moolkum, P., Jirasuksiri, S., Niyomtham, W., Chindamporn, A., 
Kajiwara, S., Prapasarakul, N., 2013. Antifungal agent susceptibilities and interpretation of 
Malassezia pachydermatis and Candida parapsilosis isolated from dogs with and without 
seborrheic dermatitis skin. Medical Mycology 51, 721–730. Available at 
doi:10.3109/13693786.2013.777165 
Zachary, J.F., McGavin, M.D., 2011. Pathologic basis of veterinary disease, 5. ed. ed. Elsevier, St. 
Louis, Mo. 
 
